Document:

Exhibit 4.3

 Exhibit 4.3 
 Execution Copy 
 EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 THIS EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (as amended from time to time,
this “Agreement”) is made as of this 1st
day of March, 2013 among Intrexon Corporation, a Virginia corporation (the “Company”), the Series Preferred Shareholders (as defined below) and certain holders of common stock of the Company (the “Existing
Shareholders”), and each other Holder (as defined below) who hereafter executes a joinder or counterpart signature page hereto and agrees to be bound by the terms hereof. 

WHEREAS, on or about the date hereof, the Company intends to issue and sell shares of its newly created No Par Value Series F Convertible
Preferred Stock (the “Series F Preferred”) to certain investors acceptable to the Company (the “Series F Investors”) pursuant to one or more Series F Convertible Preferred Stock Purchase Agreements (the
“Series F Purchase Agreements”); 
 WHEREAS, it shall be a condition precedent to the obligations of the
Company and the Series F Investors under the Series F Purchase Agreements that the Investors’ Rights Agreement, dated May 26, 2011, among the Company and the Existing Shareholders (as amended through the date hereof, the “Seventh
Investors’ Rights Agreement”) be amended and restated in its entirety in the form of this Agreement, and that the Series F Investors execute a joinder or counterpart signature page hereto and agree to be bound by the terms hereof;

 WHEREAS, pursuant to Section 8.7(b) of the Seventh Investors’ Rights Agreement, the signature of the Company
and a majority in interest of the Holders (as defined below), including a majority in interest of the Series C-3 Shareholders (as defined below) are required in order to amend and restate the Seventh Investors’ Rights Agreement in the form of
this Agreement; 
 WHEREAS, the undersigned parties, other than the Company, constitute a majority in interest of the Holders;
and 
 WHEREAS, upon its execution by the undersigned, this Agreement will be binding upon the Existing Shareholders in addition
to the undersigned. 
 NOW, THEREFORE, the Company and the undersigned Holders, including a majority in interest of the Series
C-3 Shareholders, hereby agree that the Seventh Investors’ Rights Agreement shall be amended and restated in its entirety by this Agreement, and the parties to this Agreement further agree as follows: 

 ARTICLE I 
 DEFINITIONS 
 Section 1.1 Definitions. 

In addition to the terms defined elsewhere herein, when used herein, the following terms shall have the meaning indicated hereunder for
purposes of this Agreement: 
 “1934 Act” shall mean the Securities Exchange Act of 1934, as amended, or any
similar successor federal statute and the rules and regulations thereunder, as the same shall be in effect from time to time. 

“Act” means the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and
regulations thereunder, as the same shall be in effect from time to time. 
 “Affiliate” shall mean, with
respect to any Person, any other Person who controls, is controlled by or is under common control with such Person. 

“Agreement” means this Agreement, together with the exhibits hereto, as the same may be amended, supplemented or modified
in accordance with the terms hereof. 
 “Amendment” has the meaning set forth in Section 8.7(b) of
this Agreement. 
 “Articles of Incorporation” means the Twelfth Amended and Restated Articles of Incorporation
of the Company, as the same may have been amended and as in effect as of the date hereof. 
 “Board” means the
Board of Directors of the Company. 
 “Change in Control” means (i) a merger, consolidation, share exchange
or other transaction involving the Company or the shareholders of the Company; (ii) the transfer by one or more of the Company’s shareholders of a number of shares of voting capital stock of the Company or any securities convertible into
or exchangeable for voting capital stock in any one year period that, pursuant to either clause (i) or (ii), results in one person or entity or an Affiliated group of persons or entities, other than the shareholders of the Company
immediately preceding the consummation of such transaction(s) either (x) owning in excess of fifty percent (50%) of the total voting capital stock of the Company taking into account issued and outstanding shares of such stock and any other
shares of such capital stock that would be issued and outstanding assuming conversion or exchange of any and all other securities of the Company so convertible or exchangeable or (y) being able to elect a majority of the Board; or
(iii) the sale, lease, abandonment, transfer or other disposition by the Company of all or substantially all its assets, excluding the grant of a security interest to a bank by the Company in all or substantially all of its assets pursuant to a
bona fide financing arrangement approved by the Board. Only for purposes of clause (ii) hereof, (a) transfers due to the death of a shareholder or (b) transfers to a member of a shareholder’s immediate family or a
trust of which the beneficiary is such immediate family member shall not be considered as transfers. 
 “Common”
means the No Par Value Common Stock of the Company. 
 “Company” has the meaning assigned to such term in the
preamble to this Agreement. 

  
 2 

 “Deferral Period” has the meaning set forth in Section 2.6(a)
of this Agreement. 
 “Demand Registration” has the meaning set forth in Section 2.2(a) of this
Agreement. 
 “Director” has the meaning set forth in Section 7.1(b) of this Agreement. 

“Effectiveness Period” has the meaning set forth in Section 2.6(a) of this Agreement. 

“Existing Shareholders” has the meaning assigned to such term in the preamble to this Agreement. 

“Financial Statements” means the Company’s balance sheet and statements of operations, cash flows and
shareholders’ equity. 
 “Form S-3” means such form under the Act as in effect on the date hereof or any
registration form under the Act subsequently adopted by the SEC in lieu of Form S-3 that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

“Fully-Exercising Investor” has the meaning set forth in Section 3.4(b) of this Agreement. 

“Holder” means any person owning or having the right to acquire Registrable Securities or any assignee or transferee
thereof, including, without limitation, any Person that receives Holder Stock in a transfer exempt from the provisions of (i) Article IV pursuant to Section 4.7(a) or (ii) Article V pursuant to
Section 5.5(a). 
 “Holder Stock” has the meaning set forth in Section 4.1 of this
Agreement. 
 “Inspector” has the meaning set forth in Section 2.6(j) of this Agreement. 

“IPO Effectiveness Date” means the date upon which the Company accomplishes a Qualified IPO. 

“Joint Directors” has the meaning set forth in Section 7.1(b) of this Agreement. 

“Major Holders” has the meaning set forth in Section 3.1. 

“Material Adverse Effect” means, subject to any applicable cure or grace periods, a material adverse effect upon any of
(a) the financial condition, operations, business or properties of the Company, (b) the ability of the Company to perform its material obligations under this Agreement or (c) the legality, validity or enforceability of this Agreement.

 “Notice” has the meaning set forth in Section 3.4(a) of this Agreement. 

  
 3 

 “Participants” has the meaning set forth in Section 4.3 of this
Agreement. 
 “Person” means any individual or group of individuals, firm, corporation, partnership, trust,
incorporated or unincorporated association, joint venture, joint stock company, limited liability company, governmental authority or other entity of any kind, and shall include any successor (by merger or otherwise) of such entity. 

“Preferred” means the Series A Preferred, the Series B Preferred, the Series B-1 Preferred, the Series C Preferred, the
Series C-1 Preferred, the Series C-2 Preferred, the Series C-3 Preferred, the Series D Preferred, the Series E Preferred and the Series F Preferred. 
 “Prohibited Transfer” has the meaning set forth in Section 4.8(a) of this Agreement. 
 “Pro Rata Share” has the meaning set forth in Section 4.2 of this Agreement. 
 “Qualified IPO” means the event of the closing of an underwritten initial public offering with aggregate offering proceeds to the Company of at least $100,000,000 (after reduction for
underwriting discounts and commissions). 
 “Records” has the meaning set forth in Section 2.6(j) of
this Agreement. 
 “Register”, “registered”, and “registration” refer to a
registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or document. 

“Registrable Securities” means (i) the Common issuable or issued upon conversion of the Series Preferred, as
applicable, owned or acquired after the date hereof by the Series Preferred Shareholders or any transferees thereof, provided that such transfer was made in accordance with the terms hereof, and (ii) any Common issued as (or issuable
upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of the shares referenced in clause (i) above, excluding in all
cases, however, any Registrable Securities sold by a Person in a transaction in which such Person’s rights are not assigned in accordance with the terms hereof. For the purposes of any determination under this Agreement, the number of shares of
Registrable Securities shall equal the sum of (y) the number of shares of Common outstanding that are Registrable Securities and (z) and the number of shares of Common issuable pursuant to then exercisable or convertible securities that
are exercisable or convertible into Registrable Securities as described in clauses (i) and (ii) above. Registrable Securities issuable upon exercise of an option to purchase equity securities of the Company or upon conversion
of another security shall be deemed outstanding for the purposes of this Agreement. 

  
 4 

 “Registration Date” has the meaning set forth in Section 2.13
of this Agreement. 
 “Right of Opportunity” shall have the meaning set forth in Section 5.3(a) of
this Agreement. 
 “Sale Notice” has the meaning set forth in Section 4.1 of this Agreement.

 “SEC” shall mean the United States Securities and Exchange Commission or any other federal agency at the time
administering the Act. 
 “Securities Filings” means the filing of a Form D, as promulgated under the Act, with
the SEC and any filings required under applicable state securities or “blue sky” laws by the Company in respect of its issuance of any the Series A Preferred, Series B Preferred, Series C Preferred, Series C-1 Preferred, Series C-2
Preferred, Series C-3 Preferred, Series D Preferred, Series E Preferred or Series F Preferred. 
 “Selling
Holder” has the meaning set forth in Section 5.1 of this Agreement. 
 “Series A
Agreements” has the meaning set forth in Section 8.11 of this Agreement. 
 “Series A
Preferred” means the Company’s No Par Value Series A Convertible Preferred Stock. 
 “Series A
Shareholders” means the holders of the Company’s Series A Preferred. 
 “Series B Preferred” means
the Company’s No Par Value Series B Convertible Preferred Stock. 
 “Series B Shareholders” means the
holders of Series B Preferred. 
 “Series B-1 Preferred” means the Company’s No Par Value Series B-1
Convertible Preferred Stock 
 “Series B-1 Shareholders” means the holders of Series B-1 Preferred. 

“Series C Preferred” means the Company’s No Par Value Series C Convertible Preferred Stock. 

“Series C Shareholders” means the holders of Series C Preferred. 

“Series C-1 Preferred” means the Company’s No Par Value Series C-1 Convertible Preferred Stock. 

“Series C-1 Shareholders” means the holders of Series C-1 Preferred. 

“Series C-2 Preferred” means the Company’s No Par Value Series C-2 Convertible Preferred Stock. 

  
 5 

 “Series C-2 Shareholders” means the holders of Series C-2 Preferred.

 “Series C-3 Preferred” means the Company’s No Par Value Series C-3 Convertible Preferred Stock.

 “Series C-3 Purchase Agreement” means the Series C-3 Convertible Preferred Stock Purchase Agreement, dated as
of December 22, 2009, between the Company and NRM VI Holdings I, LLC, a Virginia limited liability company. 

“Series C-3 Shareholders” means the holders of the Series C-3 Preferred. 

“Series C-3 Transaction Documents” means collectively, this Agreement, applicable joinders thereto, and the Series C-3
Purchase Agreement. 
 “Series D Preferred” means the Company’s No Par Value Series D Convertible Preferred
Stock. 
 “Series D Purchase Agreements” means the Series D Convertible Preferred Stock Purchase Agreements,
dated on or about February 19, 2010, May 4, 2010, November 1, 2010, January 6, 2011 and February 25, 2011, between the Company and the Series D Shareholders. 

“Series D Shareholders” means the holders of the Series D Preferred. 

“Series D Transaction Documents” means collectively, this Agreement, applicable joinders thereto, and the Series D
Purchase Agreements. 
 “Series E Preferred” means the Company’s No Par Value Series E Convertible
Preferred Stock. 
 “Series E Purchase Agreements” means the Series E Convertible Preferred Stock Purchase
Agreements, dated on on or about May 26, 2011, December 23, 2011, April 11, 2012 and October 26, 2012, between the Company and the Series E Shareholders. 

“Series E Shareholders” means the holders of Series E Preferred. 

“Series E Transaction Documents” means collectively, this Agreement, applicable joinders hereto, and the Series E
Purchase Agreements. 
 “Series F Investors” has the meaning assigned such term in the recitals to this
Agreement. 
 “Series F Preferred” has the meaning assigned such term in the recitals to this Agreement.

 “Series F Purchase Agreements” has the meaning assigned to such term in the recitals to this Agreement.

  
 6 

 “Series F Shareholders” means the holders of Series F Preferred.

 “Series F Transaction Documents” means collectively, this Agreement, applicable joinders hereto, and the
Series F Purchase Agreements. 
 “Series Preferred” means the Series A Preferred, Series B Preferred, Series B-1
Preferred, Series C Preferred, Series C-1 Preferred, Series C-2 Preferred, Series C-3 Preferred, Series D Preferred, Series E Preferred and Series F Preferred. Each series of Series Preferred is sometimes referred to herein as a “Series.”

 “Series F Preferred Director” has the meaning set forth in Section 7.1(a) of this Agreement.

 “Series Preferred Shareholders” means the Series A Shareholders, Series B Shareholders, Series B-1
Shareholders, Series C Shareholders, Series C-1 Shareholders, Series C-2 Shareholders, Series C-3 Shareholders, Series D Shareholders, Series E Shareholders and Series F Shareholders. 

“Seventh Investors’ Rights Agreement” has the meaning assigned to such term in the preamble to this Agreement.

 “Shares” means any of the Common or the Series Preferred or other securities convertible into or exercisable
for any shares of any class of capital stock or any combination thereof. 
 “Tag Along Right” has the meaning
set forth in Section 4.2 of this Agreement. 
 “Transaction Documents” means collectively, the
Series C-3 Transaction Documents, the Series D Transaction Documents, the Series E Transaction Documents and the Series F Transaction Documents. 
 “Violation” has the meaning set forth in Section 2.10(a) of this Agreement. 
 “Unpurchased Shares” has the meaning set forth in Section 5.3(b) of this Agreement. 
 “U.S. GAAP” means generally accepted accounting principles in effect from time to time in the United States of America. 

ARTICLE II 

REGISTRATION RIGHTS 
 Section 2.1 General; Securities Subject to this Agreement. 
  

	 	(a)	The Company hereby grants registration rights to the Series Preferred Shareholders upon the terms and conditions set forth in this Agreement. 

  
 7 

	 	(b)	For the purposes of this Agreement, Registrable Securities will cease to be Registrable Securities when (i) a registration statement covering such Registrable
Securities has been declared effective under the Act by the SEC and such Registrable Securities have been disposed of pursuant to such effective registration statement, (ii) the entire amount of Registrable Securities proposed to be sold by a
Holder in a single sale, in the opinion of counsel satisfactory to the Company and the Holder, each in their reasonable judgment, may be distributed to the public without any limitation as to volume pursuant to Rule 144 (or any successor provision
then in effect) under the Act, (iii) the Registrable Securities are proposed to be sold or distributed by a Person not entitled to the registration rights granted by this Agreement or (iv) three (3) years have elapsed since the IPO
Effectiveness Date. 

  

	 	(c)	A Person is deemed to be a Holder whenever such Person owns of record Registrable Securities, or holds an option to purchase, or a security convertible into or
exercisable or exchangeable for, Registrable Securities whether or not such acquisition or conversion has actually been effected and disregarding any legal restrictions upon the exercise of such rights. If the Company receives conflicting
instructions, notices or elections from two (2) or more Persons with respect to the same Registrable Securities, the Company may act upon the basis of the instructions, notice or election received from the registered owner of such Registrable
Securities. 

 Section 2.2 Demand Registration. 

 

	 	(a)	 If the Company shall receive at any time after the earlier of (i) three (3) years after the date hereof or (ii) the IPO Effectiveness
Date a written request from greater than seventy-five percent (75%) in interest of the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders, voting together as a single class, that the
Company register, under the Act (other than pursuant to a registration statement on Form S-4 or S-8 or any successor thereto) and under the securities or “blue sky” laws of any jurisdiction designated by such Holder or Holders (a
“Demand Registration”), the number of Registrable Securities held by such Holders and any Affiliate thereof stated in such request, then the Company shall (i) within ten (10) days of receipt thereof, give written notice of
such request to all Series E Shareholders and Series D Shareholders who own more than twenty percent (20%) of the outstanding shares of such respective Series as well as to (x) the Series F Shareholders, other than any Series F Shareholder
who has sent a prior written notice to the Company that such Series F Shareholder does not want to receive any such notice of a Demand Registration, and (y) the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders
and the Series C Shareholders not participating in the request for a Demand Registration (collectively, the “Non-Demanding Shareholders”) and (ii) take such steps as are

  
 8 

	 	
necessary to prepare for the registration of the Registrable Securities and file as soon as practicable, and in any event within forty-five (45) days of the receipt of such request, a
registration statement under the Act covering all Registrable Securities that the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders request to be registered, including any shares held by
Affiliates of such Holders and any shares requested to be included in such registration by the Non-Demanding Shareholders within ten (10) days of receipt of written notice of such registration by such Holders, subject to the limitations
contained herein. Notwithstanding the foregoing, the Company shall not be obligated to effect more than two (2) Demand Registrations pursuant to this Section 2.2. If at the time of any request to register Registrable Securities
pursuant to this Section 2.2, the Company (i) is engaged in, or has fixed plans to engage in within one hundred eighty (180) days of the time of such request, a Qualified IPO, (ii) delivers notice to the Series C-3
Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders requesting such registration within thirty (30) days of such registration request of its intent to file a registration statement for a
Qualified IPO within ninety (90) days, or (iii) is engaged in any other activity that, in the good faith determination of the Board, would be adversely affected by the requested registration and cause material detriment to the Company,
then the Company may, at its option, direct that such request be delayed for a reasonable period not in excess of one hundred twenty (120) days from the date of such request, such right to delay a request to be exercised by the Company not more
than once in any twelve (12) month period. In addition, the Company shall not be required to effect any registration within ninety (90) days after the effective date of any other registration statement of the Company (other than a
registration statement on Form S-4 or S-8 or any successor thereto). Each request for a Demand Registration shall state the amount of the Registrable Securities proposed to be sold and the intended method of disposition thereof.

  

	 	(b)	 If the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders initiating the registration
request intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.2(a). The underwriter or underwriters
shall be selected by the Company and shall be reasonably acceptable to greater than seventy-five percent (75%) in interest of the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders,
voting together as a single class. The Non-Demanding Shareholders and the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders proposing to distribute their securities through such
underwriting shall (together with the Company as provided in Section 2.6(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting.

  
 9 

	 	
Notwithstanding any other provision of this Section 2.2, if the underwriter advises the Non-Demanding Shareholders and the Series C-3 Shareholders, the Series C-2 Shareholders, the
Series C-1 Shareholders and the Series C Shareholders in writing that market factors require a limitation of the number of shares to be underwritten, then the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the
Series C Shareholders initiating such registration shall so advise all holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the
underwriting shall be allocated among the Non-Demanding Shareholders and the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders initiating such registration in proportion to the amount of
Shares owned by each such Holder and their respective Affiliates; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities are first entirely
excluded from the underwriting. If any Non-Demanding Shareholder that has requested inclusion in such registration in accordance with the terms hereof does not agree to the terms of any such underwriting agreed to by the Company, the underwriter and
the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders initiating the registration, such Non-Demanding Holder shall be excluded therefrom by written notice from the Company, the
underwriter or the Holders initiating the registration. The Registrable Securities so excluded also shall be withdrawn from registration. If shares are so withdrawn from the registration and if the number of shares to be included in such
registration was previously reduced as a result of marketing factors pursuant to this Section 2.2(b), then the Company shall offer to all Holders who have retained the right to include Registrable Securities in the registration the right
to include additional securities in the registration in an amount equal to the number of shares so withdrawn, with such shares to be allocated in proportion to the amount of Registrable Securities owned by each Holder. 

 

	 	(c)	 The Company shall use its best efforts to cause any such Demand Registration to become and remain effective as soon as practicable, but in any event
not later than ninety (90) days after it receives a request under Section 2.2(a) hereof. A registration shall not constitute a Demand Registration until it has become effective and remains continuously effective for the lesser of
(i) the period during which all Registrable Securities registered in the Demand Registration are sold and (ii) one hundred eighty (180) days; provided, however, that a registration shall not constitute a Demand Registration if
(x) after such Demand Registration has become effective, such registration or the related offer, sale or distribution of Registrable Securities thereunder is interfered with by any stop order, injunction or other order or requirement of the SEC
or other governmental agency or court for any reason not attributable to the Series 

  
 10 

	 	
C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders and such interference is not thereafter eliminated in a reasonable period of time,
(y) the conditions to closing specified in the underwriting agreement, if any, entered into in connection with such Demand Registration are not satisfied or waived, other than by reason of a failure by the Series C-3 Shareholders, the Series
C-2 Shareholders, the Series C-1 Shareholders or the Series C Shareholders or (z) if the request for such Demand Registration is withdrawn by the requesting Holders and such Holders reimburse the Company for any expenses incurred in relation
thereto. 

 Section 2.3 Company Registration. 

If (but without any obligation to do so) the Company proposes to register any of its Common under the Act in connection with an
underwritten offering of such Common for its own account (other than a registration statement on Form S-4 or S-8 or any successor thereto), then the Company shall give written notice of such proposed filing to the Holders at least thirty
(30) days before the anticipated filing date, and such notice shall describe the proposed registration and distribution and offer such Holders the opportunity to register the number of Registrable Securities as the Holders may request. Upon the
written request of any Holder given within twenty (20) days after mailing of such notice by the Company in accordance with Section 8.5, the Company shall, subject to the provisions of Section 2.6, cause to be registered
under the Act all of the Registrable Securities that the Holders requested to be registered. 
 Section 2.4 Form S-3
Registration. 
  

	 	(a)	 In case the Company shall receive from any Holder or Holders a written request or requests that the Company effect a registration on Form S-3 and any
related “blue sky” law qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holders (which amount of Registrable Securities shall have a fair market value of at least $500,000 in the
aggregate, based upon the last sales price of the Common on a national exchange or over-the-counter market, as applicable, on the day immediately preceding the date of such request), the Company will (i) promptly give notice of the proposed
registration, and any related “blue sky” law qualification or compliance, to all other Holders and (ii) as soon as practicable, but in any event not more than thirty (30) days after its receipt of such request, effect such
registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders’ Registrable Securities as are specified in such request,
together with all or such portion of the Registrable Securities of any other Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company;
provided, however, that the Company shall not be obligated to effect any such registration, “blue 

  
 11 

	 	
sky” law qualification or compliance, pursuant to this Section 2.4: (w) if Form S-3 is not available for such offering by the Holders; (x) if the Holders, together with
the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (after deduction of any underwriters’
discounts or commissions) of less than $500,000; (y) if the Company has, within the twelve (12) month period preceding the date of such request, already effected one (1) such registration on Form S-3 for the Holders pursuant to this
Section 2.4; or (z) if the Company shall furnish to the initiating Holders a certificate signed by the Chief Executive Officer or President of the Company stating that in the good faith judgment of the Board, it would be materially
detrimental to the Company and its shareholders for such Form S-3 Registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than
sixty (60) days after receipt of the request of the Holders under this Section 2.4. 

  

	 	(b)	Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon
as practicable after receipt of the request or requests of the Holders. 

  

	 	(c)	No registration requested by any Holder pursuant to this Section 2.4 shall be deemed a Demand Registration pursuant to Section 2.2.

 Section 2.5 Restrictions on Public Sale by the Company. 

The Company agrees not to effect any public sale or distribution of any Shares (except (i) pursuant to registrations on Form S-4 or
S-8 or any successor thereto or (ii) for those securities being sold by the Company pursuant to a registration statement in which the Holders of Registrable Securities are participating) during the period beginning on the effective date of any
registration statement in which the Holders of Registrable Securities are participating and ending on the earlier of (i) the date on which all Registrable Securities registered on such registration statement are sold or (ii) one hundred
eighty (180) days after the effective date of such registration statement. 
 Section 2.6 Obligations of the
Company. 
 Whenever required under this Article II to effect the registration of any Registrable Securities, the
Company shall, as expeditiously as reasonably possible: 
  

	 	(a)	 Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its reasonable best efforts to cause such
registration statement to become effective, and, upon the request of the 

  
 12 

	 	
Holders of a majority of the votes then represented by the Registrable Securities held by the Holders registered thereunder, keep such registration statement effective for a period of up to one
hundred eighty (180) days or until the distribution contemplated in the registration statement has been completed (the “Effectiveness Period”); provided, however, that (i) the Effectiveness Period shall be extended
for a period of time equal to the period the Holders refrain from selling any securities included in such registration at the request of an underwriter of Common (or other securities) of the Company; and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, the Effectiveness Period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are
sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Act governing the obligation to file a post-effective
amendment permit, in lieu of filing a post-effective amendment that (x) includes any prospectus required by Section 10(a)(3) of the Act or (y) reflects facts or events representing a material or fundamental change in the information
set forth in the registration statement, the incorporation by reference of information required to be included in (x) and (y) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the 1934 Act in the
registration statement. In the event that, in the good faith and reasonable judgment of the Company, it is advisable to suspend use of the prospectus relating to such registration statement for a discrete period of time (a “Deferral
Period”) due to pending material corporate developments or similar material events that have not yet been publicly disclosed and as to which the Company believes public disclosure will be prejudicial to the Company, the Company shall
deliver a certified resolution of the Board, signed by a duly authorized officer of the Company, to each Holder of Registrable Securities covered by such registration statement, to the effect of the foregoing and, upon receipt of such certificate,
such Holders agree not to dispose of such Holders’ Registrable Securities covered by such registration or prospectus (other than in transactions exempt from the registration requirements under the Act); provided, however, that such
Deferral Period shall be no longer than forty-five (45) days and that there may be only one Deferral Period during any twelve (12) month period. The Effectiveness Period shall be extended for a period of time equal to such Deferral Period.

  

	 	(b)	Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as
may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement. 

  
 13 

	 	(c)	Furnish to the Holders of Registrable Securities covered by such registration statement such numbers of copies of a prospectus, including any preliminary prospectus,
and any amendment or supplement thereto and a reasonable number of copies of the then-effective registration statement and any post-effective amendment thereto, all in conformity with the requirements of the Act, and such other documents as they may
reasonably request in order to facilitate the disposition of such Registrable Securities. 

  

	 	(d)	Use its reasonable best efforts to register and qualify the securities covered by such registration statement under such other securities or “blue sky” laws
of such jurisdictions, and to continue such qualification in effect in such jurisdictions, as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to
qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 

  

	 	(e)	In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing
underwriter of such offering; provided that each Holder participating in such underwriting shall also enter into and perform its obligations under such underwriting agreement. 

 

	 	(f)	Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the
Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and at the request of any such Holder prepare and furnish to such Holder a reasonable number of copies of a supplement or an
amendment to such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 

  

	 	(g)	Cause all such Registrable Securities registered pursuant hereto to be listed on each securities exchange or automated quotation system on which shares of Common are
then listed. 

  

	 	(h)	Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereto and a CUSIP number for all such Registrable Securities, in each case
not later than the effective date of such registration. 

  
 14 

	 	(i)	Permit a single firm of counsel designated as selling shareholders’ counsel by the holders of a majority of the shares of Series F Preferred, Series E Preferred,
Series D Preferred, Series C-3 Preferred and Series C-2 Preferred participating in such registration, or, in the event no Series F Shareholders, Series E Shareholders, Series D Shareholders, Series C-3 Shareholders or Series C-2 Shareholders are
participating in such registration, by the holders of a majority of shares of Series C-1 Preferred participating in such registration, or, in the event no Series C-1 Shareholders are participating in such registration, by the holders of a majority
of shares of Series C Preferred participating in such registration, or, in the event no Series C Shareholders are participating in such registration, by the holders of a majority of shares of Series B-1 Preferred participating in such registration,
or, in the event no Series B-1 Shareholders are participating in such registration, by the holders of a majority of shares of Series B Preferred participating in such registration, or, in the event no Series B Shareholders are participating in such
registration, by the holders of a majority of shares of Series A Preferred participating in such registration, to review, at the expense of the Holders, the registration statement and all amendments and supplements thereto a reasonable period of
time prior to their filing with the SEC and state authorities, and shall not file any document in a form to which such counsel reasonably objects. 

  

	 	(j)	Make available for inspection by any seller of Registrable Securities, any managing underwriter participating in any disposition pursuant to such registration
statement, Holders’ counsel and any attorney, accountant or other agent retained by any such seller or any managing underwriter (each, an “Inspector” and collectively, the “Inspectors”), all financial and other
records, pertinent corporate documents and properties of the Company (collectively, the “Records”) as shall be reasonably necessary to enable them to exercise their due diligence responsibility, and cause the Company’s
officers, directors and employees, and the independent public accountants of the Company, to supply all information reasonably requested by any such Inspector in connection with such registration statement. Records that the Company determines, in
good faith, to be confidential and of which it notifies the Inspectors are confidential shall not be disclosed by the Inspectors unless (x) the disclosure of such Records is necessary to avoid or correct a material misstatement or omission in
the registration statement, (y) the release of such Records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction or (z) the information in such Records was known to the Inspectors on a non-confidential
basis prior to its disclosure by the Company or has been made generally available to the public. Each seller of Registrable Securities agrees that it shall, upon learning that disclosure of such Records is sought in a court of competent
jurisdiction, give notice to the Company and allow the Company, at the Company’s expense, to undertake appropriate action to prevent disclosure of the Records deemed confidential. 

  
 15 

	 	(k)	If such sale is pursuant to an underwritten offering, use its reasonable best efforts to obtain a “cold comfort” letter from the Company’s independent
public accountants in customary form and covering such matters of the type customarily covered by “cold comfort” letters as Holders’ counsel or the managing underwriter reasonably request. 

 

	 	(l)	Use its reasonable best efforts to furnish, at the request of any seller of Registrable Securities on the date such securities are delivered to the underwriters for
sale pursuant to such registration or, if such securities are not being sold through underwriters, on the date the registration statement with respect to such securities becomes effective, an opinion, dated such date, of counsel representing the
Company for the purposes of such registration, addressed to the underwriters, if any, and to the seller making such request, covering such legal matters with respect to the registration in respect of which such opinion is being given as such
underwriters, if any, and such seller may reasonably request and are customarily included in such opinions and are reasonably acceptable to counsel representing the Company. 

 

	 	(m)	Otherwise use its reasonable best efforts to comply with all applicable rules and regulations of the SEC, and make available to its security holders, as soon as
reasonably practicable but no later than fifteen (15) months after the effective date of the registration statement, an earnings statement covering a period of twelve (12) months beginning after the effective date of the registration
statement, in a manner which satisfies the provisions of Section 11(a) of the Act and Rule 158 thereunder. 

  

	 	(n)	Cooperate with each seller of Registrable Securities and each underwriter participating in the disposition of such Registrable Securities and their respective counsel
in connection with any filings required to be made with the Financial Industry Regulatory Authority, Inc. 

  

	 	(o)	Use its reasonable best efforts to take all other steps necessary to effect the registration of the Registrable Securities contemplated hereby.

 Section 2.7 Furnish Information. 

It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Article II with respect to
the Registrable Securities that any selling Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the
registration of such Registrable Securities. 

  
 16 

 Section 2.8 Expenses of Registration. 

 

	 	(a)	Except as set forth in Section 2.8(b), the Company shall bear and pay all expenses incurred in connection with any registration, filing or qualification of
Registrable Securities with respect to two (2) registrations pursuant to Section 2.2, any registrations pursuant to Section 2.3 and any registrations pursuant to Section 2.4 hereof, including (without
limitation) all registration, filing and qualification fees, printers’ and accounting fees, “blue sky” fees and expenses, including fees and disbursements of counsel (up to $20,000) related to all “blue sky” matters, fees
and expenses of listing any Registrable Securities on any securities exchange or automated quotation system on which shares of Common are then listed, fees and disbursements of counsel for the Company, but excluding stock transfer taxes that may be
payable by the selling Holders, the fees and expenses of any counsel pursuant to Section 2.6(i), the fees and expenses of any Inspectors pursuant to Section 2.6(j) and underwriting discounts and commissions relating to
Registrable Securities covered by such registration, which shall be borne pro rata by the Holders. Expenses for any and all registrations not specifically payable by the Company pursuant to this Section 2.8(a) shall be borne
pro rata by the selling shareholders based on the number of shares of Registrable Securities sold by each such selling shareholder in the offering. 

  

	 	(b)	Notwithstanding Section 2.8(a), the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to
Section 2.2 if the registration request is subsequently withdrawn at the request of the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders holding a majority of the votes
represented by Shares to be registered (in which case all participating holders shall bear such expenses), unless the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders holding a majority
of the votes represented by the Shares to be registered agree to forfeit their right to one of the demand registrations to which they are entitled pursuant to Section 2.2; provided, however, that if such withdrawal occurs prior to
the date the registration statement shall have become effective and at the time of such withdrawal, the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders have learned of a material
adverse change in the financial condition, business, prospects, properties or results of operations of the Company from that known to such Holders at the time of their request and have withdrawn the request with reasonable promptness following
disclosure by the Company of such material adverse change, then the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders shall retain their respective rights pursuant to
Section 2.2 and the selling Holders shall not be required to pay any of such expenses. 

  
 17 

 Section 2.9 Underwriting Requirements. 

In connection with any offering involving an underwriting of shares of Common being issued by the Company, the Company shall be required
under Section 2.3 to include any Registrable Securities held by the Holders in such underwriting on the same terms and conditions as the securities of the Company included therein, but only in such quantity as the underwriters determine
in their good faith judgment and written opinion will not jeopardize the success of the offering by the Company. If such written opinion states that the registration of all or part of the Registrable Securities that the Holders have requested to be
included would materially adversely affect such offering, then the Company shall be required to include in such registration, to the extent of the amount that the underwriters believe may be sold without jeopardizing the success of the offering,
first, all of the securities to be offered for the account of the Company; second, the Registrable Securities to be offered for the account of the Series F Shareholders, Series E Shareholders, the Series D Shareholders and Series C-3
Shareholders, pro rata, on an as-if-converted basis, based upon the amount recommended by the underwriters; third, the Registrable Securities to be offered for the account of the Series C-2 Shareholders, pro rata based upon the
amount recommended by the underwriters; fourth, the Registrable Securities to be offered for the account of the Series C-1 Shareholders, pro rata based upon the amount recommended by the underwriters; fifth, the Registrable
Securities to be offered for the account of the Series C Shareholders, pro rata based upon the amount recommended by the underwriters; sixth, the Registrable Securities to be offered for the account of the Series B-1 Shareholders,
pro rata based upon the amount recommended by the underwriters; seventh, the Registrable Securities to be offered for the account of the Series B Shareholders, pro rata based upon the amount recommended by the underwriters;
eighth, the Registrable Securities to be offered for the account of the Series A Shareholders, pro rata based upon the amount recommended by the Underwriters; and ninth, any other shares of Common required to be included in such
underwriting and so requested to be included, pro rata based upon the amount recommended by the underwriters; provided, however, that the aggregate value of the Registrable Securities to be included in such registration by the Holders
may not be so reduced to less than twenty-five percent (25%) of the total value of all securities included in such registration, unless such offering is a Qualified IPO of the Company’s securities, in which case the selling Holders may be
excluded if the underwriters make the determination described above and no other shareholders’ securities are included. For purposes of the preceding sentence concerning apportionment, for any selling shareholder that is a Holder of Registrable
Securities that is a partnership, limited liability company or corporation, the partners, retired partners, members and shareholders of such Holder, or the estates and family members of any such partners and retired partners or members and any
trusts for the benefit of any of the foregoing persons and Affiliates of such Holder shall be deemed to be a single “selling shareholder,” and any pro rata reduction with respect to such “selling shareholder” shall be
based upon the aggregate amount of Registrable Securities owned by all entities and individuals included in such “selling shareholder,” as defined in this sentence. 

  
 18 

 Section 2.10 Indemnification. 

In the event any Registrable Securities are included in a registration statement under this Article II: 

 

	 	(a)	To the extent permitted by law, the Company will indemnify and hold harmless each Holder and their respective officers, directors, trustees, partners, employees,
advisors and agents, any underwriter (as defined in the Act) for such Holder and each Person or entity, if any, who controls such Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages, expenses or
liabilities (joint or several) to which they may become subject under the Act or the 1934 Act, insofar as such losses, claims, damages, expenses or liabilities (or actions in respect thereof) arise out of or are based upon any of the following
statements, omissions or violations (collectively, a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final
prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or
(iii) any violation or alleged violation by the Company of the Act, the 1934 Act, or any rule or regulation promulgated under the Act or the 1934 Act; and the Company will reimburse, as incurred, the Holders and any officer, director, partner,
underwriter or controlling person of the Holders, for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the
indemnity agreement contained in this Section 2.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent
shall not be unreasonably withheld, delayed or conditioned), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that occurs in
reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder or any officer, director, partner, employee, advisor, agent, underwriter or controlling person of such Holder.

  

	 	(b)	 To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who has
signed the registration statement, each Person, if any, who controls the Company within the meaning of the Act and any underwriter against any losses, claims, damages, expenses or liabilities (joint or several) to which any of the foregoing Persons
may become subject, under the Act or the 1934 Act insofar as such losses, claims, damages, expenses or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that
such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such 

  
 19 

	 	
registration; and each such Holder will reimburse, as incurred, any legal or other expenses reasonably incurred by any Person intended to be indemnified pursuant to this
Section 2.10(b), in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this Section 2.10(b) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld, delayed or conditioned); provided further,
that, in no event shall the aggregate indemnity payments under this Section 2.10(b) exceed the aggregate proceeds (net of underwriting discounts and commissions) from the sale of the Registrable Securities received by such Holder from
the shares sold by such Holder in the offering in question. 

  

	 	(c)	Promptly after receipt by an indemnified party under this Section 2.10 of notice of the commencement of any action (including any governmental action), such
indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.10, deliver to the indemnifying party a written notice of the commencement thereof; provided, however, that
the failure to so notify the indemnifying party shall not relieve the indemnifying party of any liability that it may have to the indemnified party hereunder. The indemnifying party shall have the right to participate in, and, to the extent the
indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. An indemnifying party shall not,
without the prior written consent of the indemnified parties, settle, compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification may be sought
hereunder by such indemnified parties (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes a release of such indemnified party reasonably acceptable
to such indemnified party from all liability arising out of such claim, action, suit or proceeding or unless the indemnifying party shall confirm in a written agreement reasonably acceptable to such indemnified party, that notwithstanding any
federal, state or common law, such settlement, compromise or consent shall not adversely affect the right of any indemnified party to indemnification as provided in this Section 2.10. 

  
 20 

	 	(d)	If the indemnification provided for in this Section 2.10 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect
to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such
loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that
resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access
to information, and opportunity to correct or prevent such statement or omission. Notwithstanding the foregoing, the liability of each Holder under this Section 2.10(d) shall be limited to an amount equal to the aggregate proceeds (net
of underwriting discounts and commissions) from the sale of the Registrable Securities received by such Holder from the shares sold by such Holder in the offering in question. 

 

	 	(e)	Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into by the Company
and one or more Holders in connection with a Qualified IPO are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control with respect to the Company and such Holders. 

 

	 	(f)	The obligations of the Company and the Holders under this Section 2.10 shall survive the completion of any offering of Registrable Securities in a
registration statement under this Article II, and otherwise. 

 Section 2.11 Assignment of
Registration Rights. 
 The rights to cause the Company to register Registrable Securities pursuant to this Article II
may be assigned (but only with all related obligations) by (a) a Holder to a transferee or assignee of such securities who, after such assignment or transfer, holds (together with its Affiliates) at least ten percent (10%) the shares of
Registrable Securities originally purchased from the Company by the transferring Holder (subject to appropriate adjustment for stock splits, stock dividends, combinations and other recapitalizations and including for purposes of such calculation the
shares of Common then issuable upon conversion of any securities of the Company), (b) a Holder to its partners, members, former partners or former members (or their estates) or Affiliates or (c) a Holder to any family member or trust for
the benefit of the Holder; provided: (i) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and 

  
 21 

 
address of such transferee or assignee and the Registrable Securities with respect to which such registration rights are being assigned; (ii) such transferee or assignee agrees in writing to
be bound by and subject to the terms and conditions of this Agreement; and (iii) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is
restricted under the Act. 
 Section 2.12 Limitations on Subsequent Registration Rights. 

From and after the date of this Agreement, the Company shall not, without the prior written consent of greater than seventy-five percent
(75%) in interest of the Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders and the Series C Shareholders, voting together as a single class, enter into any agreement with any holder or prospective holder of any
securities of the Company (other than Series E Shareholders who become party to this Agreement) that would allow such holder or prospective holder (a) to include such securities in any registration filed under Section 2.2,
Section 2.3 or Section 2.4 hereof, unless under the terms of such agreement, such holder or prospective Holder may include such securities in any such registration only to the extent that the inclusion of such Holder’s
securities will not reduce the amount of the Registrable Securities of the Series C-3 Shareholder, the Series C-2 Shareholders, the Series C-1 Shareholders or the Series C Shareholders that are included or (b) to effect a registration that
could result in such registration statement being declared effective prior to the earlier of either of the dates set forth in Section 2.2(a) or within 180 days of the effective date of any registration effected pursuant to
Section 2.2, Section 2.3 or Section 2.4. 
 Section 2.13 Termination of Registration
Rights. 
 No Holder shall be entitled to exercise any right provided for in this Article II after the earlier of
(i) five (5) years following the IPO Effectiveness Date (the “Registration Date”) and (ii) the date after the IPO Effectiveness Date on which a Holder can sell all shares of Registrable Securities issued to it
pursuant to Rule 144(b) under the Act, provided, however, that notwithstanding clause (ii) above, a Holder shall be entitled to exercise its rights under this Article II so long as (x) five (5) years have not elapsed
since the Registration Date and (y) such Holder (together with its Affiliates) owns more than one percent (1%) of the outstanding capital stock of the Company. 
 Section 2.14 “Market Stand-Off” Agreement. 
 Each Holder
hereby agrees that, during the period of duration specified by the Company and an underwriter of Common or other securities of the Company, following the IPO Effectiveness Date, it shall not, to the extent requested in writing by the Company and
such underwriter, directly or indirectly sell, offer to sell, contract to sell or dispose of (other than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except Common included in
such registration; provided, however, that: 
  

	 	(a)	such agreement shall be applicable only to the first registration statement of the Company which covers securities to be sold on its behalf in a Qualified IPO;

  
 22 

	 	(b)	all officers and directors of the Company and all holders of at least one percent (1%) of the Company’s outstanding Common are also subject to such a market
stand-off period; and 

  

	 	(c)	such market stand-off time period shall not exceed one hundred eighty (180) days. 

In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the securities of the
Company held by each Holder (and the shares or securities of every person subject to the foregoing restriction) until the end of such period. 
 Notwithstanding the foregoing, the obligations described in this Section 2.14 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar
forms that may be promulgated in the future, or a registration relating solely to a Rule 145 transaction under the Act. 

ARTICLE III 

COVENANTS OF THE COMPANY 
 Section 3.1 Delivery of Financial Statements and Other Information. 

So long as the Series F Shareholders, Series C-3 Shareholders, the Series C-2 Shareholders, the Series C-1 Shareholders or the Series C
Shareholders continue to own any shares of the Series F Preferred, Series C-3 Preferred, the Series C-2 Preferred, the Series C-1 Preferred, the Series C Preferred or any Common issued upon conversion of the Series F Preferred, Series C-3 Preferred,
the Series C-2 Preferred, the Series C-1 Preferred or the Series C Preferred, the Company shall deliver to each of the Series Preferred Shareholders who, together with their Affiliates, own more than twenty percent (20%) of the outstanding
shares of a given Series or who, together with their Affiliates, have invested at least an aggregate of $10,000,000 in the Company (collectively, the “Major Holders”), in form and substance satisfactory to the Series F Shareholders
and the Series C-3 Shareholders: 
  

	 	(a)	 as soon as available, but not later than one hundred and twenty (120) days after the end of each fiscal year of the Company after the date hereof,
a copy of the Company’s audited Financial Statements as of the end of and for such fiscal year, setting forth in comparative form the figures for the previous year, all in reasonable detail and accompanied by the opinion of a an independent
registered public accounting firm, which report shall state 

  
 23 

	 	
without qualification that such Financial Statements present fairly the financial condition as of such date and results of operations and cash flows for the periods indicated in conformity with
U.S. GAAP applied on a consistent basis; 

  

	 	(b)	as soon as available, but in any event not later than forty-five (45) days after the end of each fiscal quarter, the unaudited balance sheet of the Company, and
the related unaudited statements of operations and cash flows for such quarter; 

  

	 	(c)	prompt notice of any material litigation or material adverse claims or disputes with respect to the Company; provided that, that the Company may take reasonable
steps to preserve the confidentiality and attorney-client privilege with respect to any such litigation, claim or dispute, including withholding such information based on advice of outside counsel or requiring a confidentiality undertaking; and

  

	 	(d)	any material document relating to Company affairs delivered to any other non-employee shareholder of the Company in such shareholder’s capacity as a shareholder,
subject to a confidentiality undertaking reasonably required by the Company. 

 Section 3.2 Right to
Inspect. 
 Each of the Major Holders, and any designee of any of the Major Holders, shall have the right, and the Company
shall permit any such Holder or such designee, after having provided reasonable notice to the Company thereof, to visit and inspect, during normal business hours, any and all properties of the Company, including the books of record and account,
other financial records and corporate records of the Company; provided, however, that with respect to any such designees, the foregoing right to inspect is conditioned on such designees’ execution of any confidentially agreement
reasonably requested by the Company in a form reasonably acceptable to the Company. The Company shall also make its officers reasonably available to any such Holder or such designee during normal business hours for the purpose of discussing the
affairs of the Company, provided however that any such request shall not materially interfere with the operation of the Company’s business. 
 Section 3.3 Termination of Information and Inspection Covenants. 
 The
covenants set forth in Section 3.1 and Section 3.2 shall terminate and be of no further force or effect when the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with a
Qualified IPO is consummated or when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall first occur. 

  
 24 

 Section 3.4 Right of First Offer. 

Subject to the terms and conditions specified in this Section 3.4, the Company hereby grants to each of the Series Preferred
Shareholders a right of first offer with respect to future sales by the Company of its Shares. 
 Except as provided in
Section 3.4(d) hereof, each time the Company proposes to offer any Shares, the Company shall first make an offering of such Shares to the Series Preferred Shareholders in accordance with the following provisions: 

 

	 	(a)	The Company shall deliver a notice by certified mail (“Notice”) to the Series Preferred Shareholders stating (i) its bona fide intention to
offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares. 

 

	 	(b)	By written notification to be received by the Company within twenty (20) calendar days after delivery of the Notice, the Series Preferred Shareholders may elect to
purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of Shares of Common then held by such shareholder bears to the total number of Shares of Common
then outstanding (assuming full conversion and exercise of all convertible or exercisable securities). The Company shall promptly, in writing, inform each shareholder that purchases all Shares available to it (“Fully-Exercising
Investor”) of any other shareholder’s failure to do likewise. During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor shall be entitled to obtain that portion of the Shares not
subscribed for by the Series Preferred Shareholders that is equal to the proportion that the number of shares of Common then issued and held by such Fully-Exercising Investor bears to the total number of shares of Common issued and held by all
Fully-Exercising Investors who wish to purchase their pro rata portion of the unsubscribed Shares (assuming full conversion and exercise of all convertible or exercisable securities). 

 

	 	(c)	 If all Shares referred to in the Notice that the Series Preferred Shareholders are entitled to obtain pursuant to Section 3.4(b) are not
elected to be obtained as provided in Section 3.4(b) hereof, the Company may, during the thirty (30) day period following the expiration of the period provided in Section 3.4(b) hereof, offer the remaining unsubscribed
portion of such Shares to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such
period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right of first offer provided under this Section 3.4 shall be deemed to be revived and such Shares shall not be offered unless
first offered to the Series Preferred Shareholders in accordance with this Section 3.4. The right of first offer in this Section 3.4 shall not be applicable (i) to the issuance or sale of

  
 25 

	 	
Common (or options therefor) to employees, directors, consultants or advisors of the Company, for the primary purpose of soliciting or retaining their employment or services, approved by the
Board, (ii) to the consummation of a Qualified IPO, (iii) to the issuance of Shares pursuant to the conversion or exercise of convertible or exercisable securities, (iv) to the issuance of Shares solely in connection with a bona
fide business acquisition by the Company, whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise, approved by the Board, (v) to Shares issued solely in connection with the establishment of credit
facilities, including equipment financings, approved by the Board, (vi) to Shares issued as dividends or distributions on the Preferred, or (vii) to Shares (or derivatives thereof) issued to strategic partners approved by the Board.

  

	 	(d)	The rights granted by the Company pursuant to this Section 3.4 shall terminate and be of no further force or effect immediately prior to the IPO
Effectiveness Date and such rights shall be reinstated if such Qualified IPO is not consummated. 

Section 3.5 Affirmative Covenants. 
 The Company agrees as follows: 
  

	 	(a)	The Company will promptly pay and discharge, or cause to be paid and discharged, when due and payable, all lawful taxes, assessments, and governmental charges or levies
imposed upon the income, profits, property or business of the Company; provided, however, that any such tax, assessment, charge or levy need not be paid if the validity thereof shall currently be contested in good faith by appropriate
proceedings and if the Company shall have set aside on its books adequate reserves with respect thereof, and provided further, that the Company will pay all such taxes, assessments, charges or levies forthwith upon the commencement of
proceedings to foreclose any lien that may have attached as security therefor. The Company will promptly pay or cause to be paid when due, or in conformance with customary trade terms, all other indebtedness incident to the operations of the Company
where the failure to pay any such indebtedness could reasonably be expected to have a Material Adverse Effect on the Company; 

  

	 	(b)	The Company will keep its material properties in good repair, working order and condition, reasonable wear and tear excepted, and from time to time make all needful and
proper repairs, renewals, replacements, additions and improvements thereto; and the Company will at all times comply with the provisions of all material leases to which it is a party or under which it occupies property so as to prevent any loss or
forfeiture thereof or thereunder; 

  
 26 

	 	(c)	Except as otherwise decided in accordance with policies adopted by the Board, the Company will keep its assets that are of an insurable character insured by
nationally-recognized insurers against loss or damage by fire, extended coverage and explosion insurance in amounts customary for companies in similar businesses similarly situated; and the Company will maintain, with nationally-recognized insurers,
insurance against other hazards, risks and liabilities to persons and property to the extent and in the manner customary for companies in similar businesses similarly situated; 

 

	 	(d)	The Company will keep true records and books of account in which full, true and correct entries will be made of all dealings or transactions in relation to its business
and affairs in accordance with U.S. GAAP applied on a consistent basis; 

  

	 	(e)	The Company shall duly observe and conform to all valid requirements of governmental authorities relating to the conduct of its business or to its property or assets
where the failure to observe and conform to such requirements could reasonably be expected to have a Material Adverse Effect on the Company; 

  

	 	(f)	The Company shall maintain in full force and effect its corporate existence, rights and franchises and all licenses and other rights to use patents, processes,
licenses, trademarks, trade names or copyrights owned or possessed by it and deemed by the Company to be material and necessary to the conduct of its business; 

 

	 	(g)	The Company will retain an independent registered public accounting firm acceptable to the holders of a majority of the shares of Series C-3 Preferred who shall certify
the Company’s Financial Statements at the end of each fiscal year. In the event the services of the independent registered public accounting firm so selected, or any firm hereafter employed by the Company are terminated, the Company will
promptly thereafter notify each of the Major Holders and will request the independent registered public accounting firm whose services are terminated to deliver to each of the Major Holders a letter from such firm setting forth the reasons for the
termination of its services. In the event of such termination, the Company will promptly thereafter engage another independent registered public accounting firm acceptable to the holders of a majority of the shares of Series C-3 Preferred. In its
notice to the Major Holders, the Company shall state whether the change of accountants was recommended or approved by the Board or any committee thereof; 

  

	 	(h)	The Company will cause each person now or hereafter employed by it not considered an executive of the Company and not bound by an employment agreement to enter into a
proprietary information and inventions agreement substantially in a form approved by the Company’s legal counsel; 

  
 27 

	 	(i)	The Company shall file the Securities Filings in the time periods required for such filings; and 

 

	 	(j)	The Company shall at all times reserve and keep available out of its authorized shares of Common, solely for the purpose of issue or delivery upon conversion or
exercise of the Preferred or other securities as provided in the Articles of Incorporation, the maximum number of shares of Common that may be issuable or deliverable upon such conversion or exercise, as the case may be. Such shares of Common are
duly authorized and, when issued or delivered in accordance with the Articles of Incorporation, shall be validly issued, fully paid and non-assessable. The Company shall issue such shares of Common in accordance with the terms of the Articles of
Incorporation, and otherwise comply with the terms hereof and thereof. 

 Section 3.6 Termination of
Certain Covenants. 
 The covenants set forth in Section 3.5 shall terminate and be of no further force or effect
upon the consummation of a Qualified IPO. 
 ARTICLE IV 

PARTICIPATION RIGHTS IN SALES BY HOLDERS 
 Section 4.1 Notice of Sales by Holders. 
 If any Holder proposes to
sell or transfer any Shares they hold (“Holder Stock”), then such selling Holder shall promptly give written notice (the “Sale Notice”) to the Company at least thirty-five (35) days prior to the proposed
closing of such sale or transfer. The Company shall provide a copy of such Sale Notice to the Series Preferred Shareholders within five (5) days of its receipt thereof. The Sale Notice shall describe in reasonable detail the proposed sale or
transfer including, without limitation, the number of shares of Holder Stock to be sold or transferred, the nature of such sale or transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. In the
event that the sale or transfer is exempted from this Article IV pursuant to the provisions of Section 4.7(a), the Sale Notice shall so state the basis for such exemption. 

Section 4.2 Right to Participate. 
 The Series Preferred Shareholders shall have the right, exercisable upon written notice to such selling Holder within fifteen (15) days after receipt of the Sale Notice from the Company, to
participate in such sale of Holder Stock on the same terms and conditions (the “Tag Along Right”). To the extent any of the Series Preferred Shareholders exercises such right of participation in accordance with the terms and
conditions set forth in this Article IV, the number of shares of Holder 

  
 28 

 
Stock that the selling Holder may sell or transfer in the transaction shall be correspondingly reduced. Any Series Preferred Shareholders may sell all or any part of that number of shares of
Common equal to the product obtained by multiplying (i) the aggregate number of shares of Holder Stock covered by the Sale Notice by (ii) a fraction, the numerator of which is the number of shares of Common (on an as-if-converted basis)
owned by the shareholder at the time of the sale or transfer and the denominator of which is the total number of shares of Common (on an as-if-converted basis) owned by the selling Holder and the Series Preferred Shareholders participating in such
sale or transfer at the time of the sale or transfer (such product being referred to herein as a shareholder’s “Pro Rata Share”). 
 Section 4.3 Notice. 
 If any Series Preferred Shareholders elects to
participate by selling all or a portion of its Shares in the selling Holder’s sale pursuant to this Article IV, the selling Holder shall provide written notice to the participating shareholders (the “Participants”)
confirming the terms of the transfer of shares held by both the Holder and the Participants, including the number of shares calculated to be each shareholder’s Pro Rata Share to be sold by each of the Holder and the Participants. 

Section 4.4 Transfer of Shares. 
 The Participant shall effect its participation in the sale by promptly delivering to the selling Holder for transfer to the prospective purchaser one or more certificates, properly endorsed for transfer,
that represent: 
  

	 	(a)	the number of shares of Common that such Participant elects to sell; or 

  

	 	(b)	that number of shares of Preferred that is at such time convertible into the number of shares of Common that the Participant elects to sell; provided, however,
that if the prospective purchaser objects to the delivery of Preferred, such Participant shall convert such Preferred into Common and deliver Common as provided in Section 4.4(a). The Company agrees to make any such conversion concurrent
with the actual transfer of such Shares of the purchaser. 

 Section 4.5 Effecting the Transfer; Refusal
of Shares. 
 The stock certificate or certificates that the Participant delivers to the selling Holder pursuant to
Section 4.4 shall be transferred to the prospective purchaser upon consummation of the sale of the Shares pursuant to the terms and conditions specified in the Sale Notice, and the selling Holder shall concurrently therewith remit to the
Participant that portion of the sale proceeds to which the Participant is entitled by reason of its participation in such sale. To the extent that any prospective purchaser or purchasers prohibits such assignment or otherwise refuses to purchase
Shares from a Participant exercising its Tag Along Right 

  
 29 

 
herein, the selling Holder shall not sell to such prospective purchaser or purchasers any Holder Stock unless and until, simultaneously with such sale, the selling Holder shall purchase such
Shares from the Participant. 
 Section 4.6 Future Participation. 

The exercise or non-exercise of the rights of the Series Preferred Shareholders hereunder to participate in one or more sales of Holder
Stock made by any selling Holder shall not adversely affect their rights to participate in subsequent sales of Holder Stock subject to this Article IV. 
 Section 4.7 Exempt Transfers. 
  

	 	(a)	Holders’ Rights. Notwithstanding the foregoing, the Tag Along Right shall not apply to (i) any pledge of Holder Stock by a Holder made pursuant to a
bona fide loan transaction that creates a mere security interest, (ii) any transfer or bona fide gift to such Holder’s ancestors, descendants (including adopted children) or spouse or to trusts for the benefit of such
persons, or (iii) any transfer by a Holder to its partners, members, former partners or former members (or their estates) or Affiliates; provided that (x) such Holder shall inform the Company of such pledge, transfer or gift prior
to effecting it, (y) the pledgee, transferee or donee shall furnish the Company with a written agreement to be bound by and comply with all provisions of this Agreement applicable to the Holder, and (z) as a result of such pledge, transfer
or gift, the Company would not, in the opinion of counsel to the Company, be rendered subject to the reporting requirements of the 1934 Act. Such pledgee, transferee or donee shall be treated as a “Holder” for purposes of this Agreement,
with corresponding rights and obligations. 

  

	 	(b)	Holders. Notwithstanding the foregoing, the provisions of Article IV shall not apply to the sale of any Holder Stock to the public pursuant to a
registration statement filed with, and declared effective by, the SEC under the Act. 

 Section 4.8
Prohibited Transfers. 
  

	 	(a)	Remedies. In the event a Holder should sell any Holder Stock in contravention of the Tag Along Right under this Agreement (a “Prohibited
Transfer”), the Participants, in addition to such other remedies as may be available at law, in equity or hereunder, shall have the put option provided in Section 4.8(b) below, and the Holder shall be bound by the applicable
provisions of such option. 

  

	 	(b)	 Sale by the Participants. In the event of a Prohibited Transfer, the Participants shall have the right to sell to such Holder the number of
shares of Common equal to the number of shares of Common the Participants would have been entitled to transfer to the purchaser had the 

  
 30 

	 	
Prohibited Transfer been effected pursuant to and in compliance with the terms of this Article IV. Such sale shall be made on the following terms and conditions: 

 

	 	(i)	Price. The price per share at which the shares are to be sold to such Holder shall be equal to the price per share paid by the purchaser to the Holder in the
Prohibited Transfer (subject to adjustment for conversion to Common, as applicable). The Holder shall also reimburse the Participants for any and all fees and expenses, including legal fees and expenses, incurred pursuant to the exercise or the
attempted exercise of the Participant’s rights under this Article IV. 

  

	 	(ii)	Delivery. Within ninety (90) days after the earlier of the dates on which the Participants (i) received notice of the Prohibited Transfer or
(ii) otherwise became aware of the Prohibited Transfer, the Participants shall, if exercising the option created by this Section 4.8(b), deliver to such Holder the certificate or certificates representing the shares of Common to be
sold, each certificate to be properly endorsed for transfer. 

  

	 	(iii)	Payment. The Holder shall, upon receipt of the certificate or certificates for the Shares to be sold by the Participants pursuant to this
Section 4.8(b), pay the aggregate purchase price therefor and the amount of reimbursable fees and expenses, as specified in Section 4.8(b)(i), in cash or by other means acceptable to the Participants.

  

	 	(iv)	Void Transfers. Notwithstanding the foregoing, any attempt by a Holder to transfer Holder Stock in violation of Article IV hereof shall be void and the
Company agrees it will not effect such a transfer nor will it treat any alleged transferee as the holder of such Shares without the written consent of a majority of the votes represented by outstanding Registrable Securities held by the Series
Preferred Shareholders. 

 Section 4.9 Legend. 

 

	 	(a)	Each certificate representing shares of Holder Stock now or hereafter owned by the Holder or issued to any person in connection with a transfer pursuant to Article
IV hereof shall be endorsed with the following legend: 

 “THE SALE, PLEDGE, HYPOTHECATION, TRANSFER AND
VOTING OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE RESTRICTED BY THE TERMS AND CONDITIONS OF A CERTAIN INVESTORS’ RIGHTS AGREEMENT BY 

  
 31 

 
AND AMONG THE SHAREHOLDERS AND THE CORPORATION. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE CORPORATION. THE CORPORATION WILL NOT REGISTER THE TRANSFER
OF SUCH SECURITIES ON THE BOOKS OF THE CORPORATION UNLESS AND UNTIL THE TRANSFER HAS BEEN MADE IN COMPLIANCE WITH THE TERMS OF SUCH AGREEMENT.” 
  

	 	(b)	Each Holder agrees that the Company may instruct its transfer agent to impose transfer restrictions on the Shares represented by certificates bearing the legend
referred to in Section 4.9(a) to enforce the provisions of this Agreement and the Company agrees to promptly do so. The legend shall be removed upon termination of this Agreement or this Article IV. 

Section 4.10 Termination of Rights and Obligations. 
 The rights and obligations set forth in this Article IV shall terminate automatically in the event of a Qualified IPO. 
 ARTICLE V 
 RIGHT OF FIRST OPPORTUNITY 

Section 5.1 General. 
 Subject to the terms and conditions of this Article V, each Holder proposing to offer any Shares for sale (a “Selling Holder”) hereby grants to the parties set forth in this
Article V a right of first opportunity with respect to future sales by such Selling Holder of shares of Holder Stock. 

Section 5.2 Initial Notice by Selling Holders. 
 Each time a Selling Holder proposes to offer any Holder Stock, such Selling Holder shall promptly provide a Sale Notice to the Company at least sixty-five (65) days prior to the proposed closing of
such sale or transfer. The Company shall provide a copy of such Sale Notice to the Series Preferred Shareholders within five (5) days of its receipt thereof. The Sale Notice shall describe in reasonable detail the proposed sale or transfer
including, without limitation, the number of shares of Holder Stock to be sold or transferred, the nature of such sale or transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. In the event the
sale or transfer is exempted from this Article V pursuant to the provisions of Section 5.5, the Sale Notice shall so state the basis for such exemption. 

  
 32 

 Section 5.3 Participation. 

 

	 	(a)	The Company and the Series Preferred Shareholders shall have the right, exercisable upon written notice to such Selling Holder within sixty (60) days after receipt
of such Sale Notice by the Series Preferred Shareholders, to elect to purchase or obtain such Holder Stock on the same terms and conditions as set forth in such Sale Notice (the “Right of Opportunity”), subject to the provisions of
this Article V. Any party electing to exercise its Right of Opportunity shall state in its written notice whether it intends to purchase (i) the maximum number of shares to which it is entitled under this Section 5.3 or
(ii) such lesser number of shares, in which case such party shall state the maximum number of shares it is willing to purchase pursuant to the exercise of its Right of Opportunity. Notwithstanding the foregoing, any Series Preferred
Shareholders electing to exercise its right to sell Shares pursuant to Article IV above shall not be eligible to participate in the Right of Opportunity under this Article V and shall waive such Right of Opportunity with respect to the
sale of Holder Stock in question. Should no response be received by the Selling Holder from the Company or the Series Preferred Shareholders within sixty (60) days after receipt of the Sale Notice by the Series Preferred Shareholders, any such
party failing to provide such notice shall forfeit such Right of Opportunity for the respective sale. 

  

	 	(b)	Should the Company make the election not to exercise its Right of Opportunity or should the Company make the election not to purchase the total number of shares of
Holder Stock offered by the Selling Holder (such shares not being purchased being referred to herein as the “Unpurchased Shares”), the eligible Series Preferred Shareholders may elect to purchase or obtain, at the price and on the
terms specified in such Sale Notice, up to that portion of the Unpurchased Shares that equals the proportion that the number of shares of Common (on an as-if-converted basis) issued and held by the applicable Holder bears to the total number of
shares of Common (on as as-if-converted basis) held by all eligible Series Preferred Shareholders electing to exercise their Right of Opportunity. 

  

	 	(c)	If all of the Shares referred to in the Sale Notice are not elected to be purchased as provided in this Section 5.3, the Selling Holder may, during the one
hundred twenty (120) day period following the expiration of the sixty (60) day period set forth in Section 5.3(a), offer the remaining Unpurchased Shares to a third party at a price not less than and upon terms no more
favorable to the offeree than those specified in the Sale Notice. If the Selling Holder does not enter into an agreement with respect to the sale of the remaining Unpurchased Shares within such one hundred twenty (120) day period, or if such
agreement in not consummated within thirty (30) days of the execution thereof, the Right of Opportunity shall be deemed to be revived and such Unpurchased Shares shall not be offered unless first reoffered in accordance with this Article
V. 

  
 33 

 Section 5.4 Future Participation. 

The exercise or non-exercise of the Right of Opportunity hereunder to participate in one or more sales of Holder Stock made by any Selling
Holder shall not adversely affect the rights of the Series Preferred Shareholders to participate in subsequent sales of Holder Stock subject to Section 5.1. 
 Section 5.5 Exempt Transfers. 
  

	 	(a)	Holders’ Rights. Notwithstanding the foregoing, the Right of Opportunity shall not apply to (i) any pledge of Holder Stock by a Selling Holder made
pursuant to a bona fide loan transaction that creates a mere security interest, (ii) any transfer or bona fide gift to such Selling Holder’s ancestors, descendants (including adopted children) or spouse or to trusts for the
benefit of such persons, or (iii) any transfer by a Holder to its partners, members, former partners or former members (or their estates) or Affiliates; provided that (x) such Selling Holder shall inform the Company of such pledge,
transfer or gift prior to effecting it, (y) the pledgee, transferee or donee shall furnish the Company with a written agreement to be bound by and comply with all provisions of this Agreement applicable to the Selling Holder, and (z) as a
result of such pledge, transfer or gift, the Company would not, in the opinion of counsel to the Company, be rendered subject to the reporting requirements of the 1934 Act. Such pledgee, transferee or donee shall be treated as a “Holder”
for purposes of this Agreement, with corresponding rights and obligations. 

  

	 	(b)	Holders. Notwithstanding the foregoing, the provisions of Article V shall not apply to the sale of any Holder Stock to the public pursuant to a
registration statement filed with, and declared effective by, the SEC under the Act. 

 Section 5.6
Termination of Rights and Obligations. 
 The rights and obligations set forth in this Article V shall terminate
automatically in the event of a Qualified IPO. 
 ARTICLE VI 

DRAG-ALONG RIGHT 
 In the event that the Board votes in favor of a transaction resulting in a Change in Control, the Holders each agree to vote their shares as recommended by the Board in favor of the transaction. In
addition, in the event that a majority in interest of the Series C-3 Shareholders and a majority in interest of the Series C-2 Shareholders enter into an agreement to sell their Shares to a third party in a transaction resulting in a Change in
Control, the Holders each agree to sell their Shares to such third party on the same terms and conditions. The provisions of this Article VI shall constitute a shareholders agreement within the meaning of Section 13.1-671.1 of the
Virginia Stock Corporation Act and shall be noted conspicuously on the front or back of each certificate for outstanding Shares. For the avoidance of doubt, all proceeds from any such transaction shall be paid to the Holders in accordance with
Article Third, Section C (Liquidation Preference) of the Articles of Incorporation. 

  
 34 

 ARTICLE VII 
 BOARD OF DIRECTORS 
 Section 7.1 Election of Directors.

  

	 	(a)	Series F Preferred Director. As long as the holders of Series F Preferred continue to hold in the aggregate at least 1.9 million shares of Series F
Preferred (subject to adjustment in the event of any stock dividend, stock split, stock distribution or combination with respect to such shares), the Company hereby agrees to take such actions as are necessary, and the Series F Preferred
Shareholders, voting as a separate voting group, agree to vote their shares of Series F Preferred and take such other actions as are necessary, so as to elect, reelect, vote or replace as Directors of the Company, one (1) individual (the
“Series F Preferred Director”) designated by the holders of at least a majority of the shares of Series F Preferred, voting together as a separate voting group. 

 

	 	(b)	Joint Directors. The Company hereby agrees to take such actions as are necessary, and each of the Series Preferred Shareholders (but as long as the Series F
Preferred Shareholders are entitled to elect the Series F Preferred Director, excluding the Series F Preferred Shareholders) and holders of Common agree to vote his, her or its Shares and take such other actions as are necessary so as to elect,
reelect, vote or replace as Directors of the Company, (i) as long as the Series F Preferred Shareholders are entitled to elect the Series F Preferred Director, seven (7) individuals, and (ii) at any time when the Series F Preferred
Shareholders are not entitled to elect the Series F Preferred Director, eight (8) individuals (the “Joint Directors”) designated by the holders of at least a majority of the shares of Series Preferred (on an as-converted to
Common basis but excluding the Series F Preferred, as appropriate) and the Common, voting together as a separate voting group . 

 The Series F Preferred Director and the Joint Directors shall collectively be referred to as the “Directors”, and each individually, a “Director.” 

 

	 	(c)	Shareholders Agreement. The provisions of Section 7.1 and Section 7.2 hereof shall constitute a shareholders agreement within the meaning
of Section 13.1-671.1 of the Virginia Stock Corporation Act and shall be noted conspicuously on the front or back of each certificate for outstanding Shares. 

Section 7.2 Removal and Substitution of Directors. 
 No Director may be removed except by the holders entitled to appoint such Director in accordance with Section 7.1 and each party hereto hereby agrees to take all action necessary (including,
without limitation, voting their respective 

  
 35 

 
shares, calling special meetings of shareholders and executing and delivery written consents) for the purpose of accomplishing the foregoing. If a vacancy on the Board occurs by reason of the
death, removal, resignation, retirement or election not to serve of a designee, the remaining Directors and the Company shall cause the vacancy thereby created to be filled by a new designee as soon as possible, who is designated in the manner and
by the persons specified in Section 7.1 and the Company and each holder hereby agrees to take, at any time and from time to time, all actions necessary to accomplish the same. 

Section 7.3 Director Compensation Plan. 
 The Company shall award each Director options to purchase Common and shall pay cash compensation pursuant to the Company’s then effective Director Compensation Plan as approved by the Company’s
Board. 
 Section 7.4 Indemnification. 
 The Articles of Incorporation and Bylaws of the Company shall at all times provide for the exculpation and indemnification of the Board to the fullest extent permitted by the law of the jurisdiction in
which the Company is organized. 
 Section 7.5 Termination. 

The provisions of Articles VI and VII shall terminate automatically in the event of a Qualified IPO. 

ARTICLE VIII 
 MISCELLANEOUS 
 Section 8.1 Successors and Assigns. 

Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 Section 8.2 Governing Law. 
 This Agreement shall be governed by and
construed in accordance with the laws of the Commonwealth of Virginia, without regard to the principles of conflicts of law thereof. 

  
 36 

 Section 8.3 Counterparts. 

This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so
executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement, and may be delivered to the other parties hereto by facsimile. 

Section 8.4 Headings. 
 The headings and subheadings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. 

Section 8.5 Notices. 
 All notices, demands and other communications provided for or permitted hereunder shall be made in writing and shall be by certified first-class mail, return receipt requested, facsimile, courier service
or personal delivery: 
  

	 	(a)	if to the Company: 

 Intrexon
Corporation 
 1750 Kraft Drive, Suite 1400 
 Blacksburg, VA 24060 
 Attention: Rick Sterling, CFO 

Facsimile: 540-961-0734 
 with copies (which shall not constitute notice) to: 
 Intrexon Corporation

 20358 Seneca Meadows Parkway 
 Germantown, MD 20876 
 Attention: Legal Department 

Facsimile: 301-556-9901 
 and 
 Troutman Sanders LLP 

1001 Haxall Point 
 Richmond, VA 23219 
 Attn: John Owen Gwathmey, Esq. 

Facsimile: 804-698-5174 
 and 
  

	 	(b)	if to any Holder, to such Holder’s record address on file with the Company. 

 All such notices and communications shall be deemed to have been duly given when delivered by hand, if personally delivered; when delivered by courier, if

  
 37 

 
delivered by commercial courier service, five (5) days of business after being deposited in the mail, postage prepaid, if mailed; and when receipt is mechanically acknowledged, if sent by
facsimile. 
 Section 8.6 Expenses. 
 If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary
disbursements in addition to any other relief to which such party may be entitled. 
 Section 8.7 Amendments and
Waivers. 
  

	 	(a)	No failure or delay on the part of any party to this Agreement in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any
single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. The remedies provided for herein are cumulative and are not exclusive of any remedies
that may be available to the parties hereto at law, in equity or otherwise. 

  

	 	(b)	Any amendment, supplement or modification of or to any provision of this Agreement, any waiver of any provision of this Agreement, and any consent to any departure by
any of the parties to this Agreement from the terms of any provision of this Agreement (collectively, an “Amendment”), shall be effective (i) only if it is made or given in writing and signed by (x) the Company, (y) a
majority in interest of the Holders and (z) a majority in interest of the Holders of the Preferred Stock, voting together as a single class on an as-converted to Common Stock basis, and (ii) only in the specific instance and for the
specific purpose for which made or given. Additionally, (A) no Amendment that affects any Series Preferred in any manner that is materially more adverse to such Series Preferred than the Holders of any other Series Preferred shall be effective
without the consent of a majority in interest of such adversely affected Series Preferred and (B) no Amendment that affects any Holder in a manner that is materially more adverse to such Holder than to a majority of the other Holders shall be
effective without the consent of such Holder. Except where notice is specifically required by this Agreement, no notice to or demand on the Company in any case shall entitle the Company to any other further notice or demand in similar or other
circumstances. 

  
 38 

 Section 8.8 Additional Legends. 

In addition to other legends required under the terms of this Agreement, in order to reflect the restrictions on the disposition of the
Shares, the stock certificates for the Shares will be endorsed upon receipt with restrictive legends, including the following legend: 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE, AND MAY BE OFFERED AND SOLD
ONLY IF REGISTERED AND QUALIFIED PURSUANT TO FEDERAL AND STATE SECURITIES LAWS OR IF THE COMPANY IS PROVIDED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION AND QUALIFICATION UNDER FEDERAL AND STATE SECURITIES LAWS IS NOT
REQUIRED.” 
 If required by the authorities of any state in connection with the issuance of the Shares, the legend or
legends required by such state authorities shall also be endorsed upon receipt on all such certificates. Such legends required under this Section 8.8 shall be removed upon registration of the Shares or upon presentation to the Company of
an opinion of counsel or other representation reasonably satisfactory to the Company that the Shares may be transferred under Rule 144(b) under the Act. 
 Section 8.9 Severability. 
 If any one or more of the provisions
contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the remaining
provisions hereof shall not be in any way impaired, unless the provision held invalid, illegal or unenforceable shall substantially impair the benefits of the remaining provisions hereof. 

Section 8.10 Rules of Construction. 
 Unless the context otherwise requires, references to sections or subsections refer to sections or subsections of this Agreement. 
 Section 8.11 Entire Agreement. 
 This Agreement, together with the
exhibits and schedules hereto, and the other Transaction Documents, as applicable, are intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the
parties hereto in respect of the subject matter contained herein and therein. There are no restrictions, promises, representations, warranties or undertakings, other than those set forth or referred to herein or therein. This Agreement, together
with the exhibits and schedules hereto, and the other Transaction Documents, supersede all prior agreements and understandings between the parties with respect to such subject matter 

  
 39 

 Section 8.12 Publicity; Confidentiality. 

 

	 	(a)	None of the Holders, except in their capacity as an officer, director or employee of the Company, shall issue a publicity release or public announcement or otherwise
make any disclosure concerning this Agreement, the transactions contemplated hereby or regarding the business, technology and financial affairs of the Company, without prior approval by the other parties hereto; provided, however, that
nothing in this Agreement shall restrict a Holder from disclosing information (i) that is already publicly available, (ii) that was known to the Holder on a non-confidential basis prior to its disclosure by the disclosing party,
(iii) that may be required or appropriate in response to any summons or subpoena or in connection with any litigation, provided that the Holder will use reasonable efforts to notify the disclosing party in advance of such disclosure so
as to permit such party to seek a protective order or otherwise contest such disclosure, and such party will use reasonable efforts to cooperate, at the expense of the disclosing party, with the disclosing party in pursuing any such protective
order, (iv) to the extent that the Holder reasonably believes it appropriate in order to protect its investment in Series Preferred or in order to comply with any requirement of law, (v) to the Holder’s officers, directors,
shareholders, agents, employees, members, partners, controlling persons, auditors or counsel, (vi) to Persons from whom releases, consents or approvals are required, or to whom notice is required to be provided, pursuant to the transactions
contemplated by the Transaction Documents or (vii) to the prospective transferee in connection with any contemplated transfer of any Shares. If any announcement is required by law or the rules of any securities exchange or market on which
shares of Common are traded to be made by any Holder, prior to making such announcement such party will deliver a draft of such announcement to the other parties and shall give the other parties reasonable opportunity to comment thereon.

  

	 	(b)	 The Company and its representatives shall not, except with the prior written consent of the applicable Series E Investor or Series F Investor, issue a
publicity release or public announcement or otherwise make any disclosure identifying such Series E Investor or Series F Investor as a party to the Transaction Documents and the transactions contemplated thereby or otherwise as an investor in the
Company; provided, however, that nothing in this Agreement shall restrict such parties from disclosing information (i) that is already publicly available, (ii) that may be required or appropriate in response to any summons or
subpoena or in connection with any litigation, provided that the Company will use reasonable efforts to notify the disclosing party in advance of such disclosure so as to permit such party to seek a protective order or otherwise contest such
disclosure, and such party will use reasonable efforts to cooperate, at the expense of the disclosing party, with the disclosing party in pursuing any such protective order, (iii) to the extent that the Company reasonably believes it

  
 40 

	 	
appropriate in order to comply with any requirement of law, (iv) to the Company’s officers, directors, shareholders, agents, employees, members, partners, controlling persons, auditors
or counsel, or (v) to Persons from whom releases, consents or approvals are required, or to whom notice is required to be provided, pursuant to the transactions contemplated by the Transaction Documents. 

Section 8.13 Waiver of Rights. 
 By signing below the undersigned Holders hereby provide all necessary consents and waivers of rights (including, without limitation, preemptive rights) required in order for the Company properly to
execute and consummate the Series F Transaction Documents, or any other Transactions Documents. 
 {Signature Page Follows}

  
 41 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and
delivered by their respective officers hereunto duly authorized on the date first above written. 
  

					
	COMPANY:	 	INTREXON CORPORATION
			
		 	By:	 	 /s/ Rick Sterling

		 		 	Rick Sterling
		 		 	Chief Financial Officer
			
	SERIES E	 		 	
	SHAREHOLDERS:	 	NRM VI HOLDINGS I, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Capital Partners VI, LLC
		 		 	which is the Manager of NRM VI Holdings I, LLC
		
		 	R.J. KIRK DECLARATION OF TRUST
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Trustee
		
		 	JPK 2009, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of JPK 2009, LLC

 
			
	MGK 2009, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of MGK 2009, LLC

  

			
	THIRD SECURITY SENIOR STAFF 2008 LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	 Manager, Third Security, LLC,

which is the Manager of Third Security Senior Staff 2008, LLC

  

			
	THIRD SECURITY STAFF 2010 LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of Third Security Staff 2010 LLC

  

			
	JPK 2008, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of JPK 2008, LLC

 
			
	MGK 2008, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of MGK 2008, LLC

  

			
	MGK 2011, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of MGK 2011, LLC

  

			
	ZSK 2008, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of ZSK 2008, LLC

  

			
	ZSK 2009, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of ZSK 2009, LLC

					
		 	THIRD SECURITY INCENTIVE 2010 LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Incentive 2010 LLC
		
		 	KAPITAL JOE, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Kapital Joe, LLC
		
		 	MASCARA KABOOM, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Mascara Kaboom, LLC
			
	SERIES D	 		 	
	SHAREHOLDERS:	 	NRM VI HOLDINGS I, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Capital Partners VI, LLC,
		 		 	which is the Manager of NRM VI HOLDINGS I, LLC

 
			
	R.J. KIRK DECLARATION OF TRUST
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Trustee
	
	JPK 2009, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of JPK 2009, LLC
	
	MGK 2009, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of MGK 2009, LLC
	
	JPK 2008, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of JPK 2008, LLC

 
			
	MGK 2008, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of MGK 2008, LLC
	
	MGK 2011, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of MGK 2011, LLC
	
	ZSK 2008, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of ZSK 2008, LLC
	
	JPK 2012, LLC
		
	By:	 	 /s/ Randal J. Kirk

		 	Randal J. Kirk
		 	Manager, Third Security, LLC,
		 	which is the Manager of JPK 2012, LLC

					
		 	ZSK 2009, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of ZSK 2009, LLC
		
		 	KELLIE L. BANKS (2009) LONG TERM TRUST
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Trustee
			
	SERIES C-3	 		 	
	SHAREHOLDERS:	 	NRM VI HOLDINGS I, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Capital Partners VI, LLC,
		 		 	which is the Manager of NRM VI Holdings I, LLC
			
	SERIES C-2	 		 	
	SHAREHOLDERS:	 	NEW RIVER MANAGEMENT V, LP
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Capital Partners V, LLC,
		 		 	which is the General Partner of New River Management V, LP

					
	SERIES C-1	 		 	
	SHAREHOLDERS:	 	NEW RIVER MANAGEMENT V, LP
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Capital Partners V, LLC,
		 		 	which is the General Partner of New River Management V, LP
			
	SERIES C	 		 	
	SHAREHOLDERS:	 	NEW RIVER MANAGEMENT IV, LP
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Capital Partners IV, LLC,
		 		 	which is the General Partner of New River Management IV, LP
		
		 	NEWVA CAPITAL PARTNERS, LP
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security RNR LLC,
		 		 	which is the General Partner of NewVa Capital Partners, LP

					
		 	MGK 2011, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of MGK 2011, LLC
		
		 	MGK 2009, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of MGK 2009, LLC
		
		 	JPK 2009, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of JPK 2009, LLC
		
		 	THIRD SECURITY STAFF 2001 LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC
		 		 	which is the Manager of Third Security Staff 2001 LLC

					
		 	R.J. KIRK DECLARATION OF TRUST
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Trustee
		
		 	JPK 2012, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC
		 		 	which is the Manager of JPK 2012, LLC
		
		 	KELLIE L. BANKS (2009) LONG TERM TRUST
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Trustee
			
	SERIES B	 		 	
	SHAREHOLDERS:	 	
		
		 	NEWVA CAPITAL PARTNERS, LP
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security RNR LLC,
		 		 	which is the General Partner of NewVa Capital Partners, LP

					
	SERIES B-1	 		 	
	SHAREHOLDERS:	 		 	
		
		 	NEWVA CAPITAL PARTNERS, LP
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security RNR LLC,
		 		 	which is the General Partner of NewVa Capital Partners, LP
			
	COMMON	 		 	
	SHAREHOLDERS:	 	NRM VI HOLDINGS I, LLC
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Capital Partners VI, LLC,
		 		 	which is the Manager of NRM VI Holdings I, LLC
		
		 	NEW RIVER MANAGEMENT V, LP
			
		 	By:	 	 /s/ Randal J. Kirk

		 		 	Randal J. Kirk
		 		 	Manager, Third Security, LLC,
		 		 	which is the Manager of Third Security Capital Partners V, LLC,
		 		 	which is the General Partner of New River Management V, LP

					
		 	THOMAS DAVID REED LIVING TRUST,
		 	DATED FEBRUARY 4, 2011
			
		 	By:	 	 /s/ Thomas David Reed

		 		 	Thomas David Reed
		 		 	Trustee
		
		 	JACQUELYN ANN REED LIVING TRUST,
		 	DATED FEBRUARY 4, 2011
			
		 	By:	 	 /s/ Jacquelyn Ann Reed

		 		 	Jacquelyn Ann Reed
		 		 	Trustee

 JOINDER TO RESTATED INVESTORS’ RIGHTS AGREEMENT 

In connection with the purchase by the undersigned (the “Joining Party”) of shares of No Par Value Series F Convertible
Preferred Stock of Intrexon Corporation, a Virginia corporation (the “Company”), the Joining Party hereby acknowledges and agrees to become party to and to succeed to all of the rights and obligations of a “Holder” and
“Series Preferred Shareholder” under that certain Eighth Amended and Restated Investors’ Rights Agreement (as amended, the “Restated IRA”), by and among the Company and the shareholders of the Company from time to
time party thereto. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Restated IRA. 
 Accordingly, the Joining Party hereby acknowledges, agrees and confirms that, by its execution of this Investors’ Rights Agreement Joinder and its acceptance by the Company, the Joining Party will be
deemed to be a party to the Restated IRA as if it had executed the Restated IRA effective as of the date this Investors’ Rights Agreement Joinder is accepted by the Company. The Joining Party hereby authorizes the Company to append this
Investors’ Rights Agreement Joinder as a counterpart signature page to the Restated IRA. 
 IN WITNESS WHEREOF, the
undersigned has executed this Investors’ Rights Agreement Joinder effective as of the date written below. 
 JOINING PARTIES:

  

							
		 	Name:	  	 Fidelity Select Portfolios: Biotechnology Portfolio
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Kenneth Robins
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Kenneth Robins
	  	
		 		  	 Treasurer
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Kenneth Robins
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Kenneth Robins
	  	
		 		  	 Treasurer
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Fidelity Contra Fund: Fidelity Series Opportunistic Insights Fund
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Kenneth Robins
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Kenneth Robins
	  	
		 		  	 Treasurer
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Fidelity Contra Fund: Fidelity Advisor Series Opportunistic Insights Fund
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Kenneth Robins
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Kenneth Robins
	  	
		 		  	 Treasurer
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 GREENLIGHT CAPITAL, LP
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Harry Brandler | /s/ Vinit Sethi
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Harry Brandler | Vinit Sethi, CFO | Director of Research
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 GREENLIGHT CAPITAL QUALIFIED, LP
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Harry Brandler | /s/ Vinit Sethi
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Harry Brandler | Vinit Sethi, CFO | Director of Research
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

							
		 	Name:	  	 GREENLIGHT CAPITAL (GOLD), LP
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Harry Brandler | /s/ Vinit Sethi
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Harry Brandler | Vinit Sethi, CFO | Director of Research
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 GREENLIGHT CAPITAL OFFSHORE PARTNERS
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Harry Brandler | /s/ Vinit Sethi
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Harry Brandler | Vinit Sethi, CFO | Director of Research
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 GREENLIGHT CAPITAL OFFSHORE MASTER (GOLD), LTD
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Harry Brandler | /s/ Vinit Sethi
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Harry Brandler | Vinit Sethi, CFO | Director of Research
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 GREENLIGHT REINSURANCE, LTD
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Harry Brandler | /s/ Vinit Sethi
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Harry Brandler | Vinit Sethi, CFO | Director of Research
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 David G. P. Allan
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ David G. P. Allan
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 The Marvin E. Ausherman Revocable Trust
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Marvin E. Ausherman
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Marvin E. Ausherman, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Bertal, LLC
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Alan Hirschfield /s/ Berte Hirschfield
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Alan Hirschfield Berte Hirschfield
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

									
		 	Name:	  	 John Bickerman
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	
				
		 	Signature:	  	 /s/ John Bickerman
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Carruthers Family Trust UA 4/1/2004
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	
				
		 	Signature:	  	 /s/ James L. Carruthers
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 James L. Carruthers, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 A. Baron Cass III
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	
				
		 	Signature:	  	 /s/ A. Baron Cass III
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 A. Baron Cass III
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 A. Baron Cass III, Trustee of H. Baron Cass III Children’s Trust, FBO A. Baron Cass IV dated
5-24-82
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	
				
		 	Signature:	  	 /s/ A. Baron Cass III
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 A. Baron Cass III, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 A. Baron Cass III, Trustee of H. Baron Cass III Children’s Trust, FBO Channing E. Cass dated
5-24-82
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	
				
		 	Signature:	  	 /s/ A. Baron Cass III
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 A. Baron Cass III, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 A. Baron Cass III, Trustee of H. Baron Cass III Children’s Trust, FBO Perry C. Cass dated
5-24-82
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	
				
		 	Signature:	  	 /s/ A. Baron Cass III
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 A. Baron Cass III, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

							
		 	Name:	  	 Stanley Ciemniecki
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Stanley Ciemniecki
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Barton J. Cohen Revocable Trust UAD 12/12/90
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Barton J. Cohen
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Stephen F. Dubord
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Stephen F. Dubord
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Falcon Fund, Ltd.
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ G. Houston Hall
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 G. Houston Hall
	  	
		 		  	 General Partner: Falcon Fund Management, Ltd.
	  	
		 		  	 FFM GP, LLC as General Partner
	  	
		 		  	 G. Houston Hall, President
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Fish Creek Partners
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Scott Hirschfield /s/ Marc Hirschfield /s/ Laura Hirschfield
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Scott Hirschfield, Marc Hirschfield, Laura Hirschfield
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Goolock Associates
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ William B. Finneran
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 William B. Finneran – General Partner
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

							
		 	Name:	  	 Sydney Ann Hall Irrevocable 2000 Exempt Trust
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Wallace L. Hall, Sr.
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Wallace L. Hall, Sr., Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Daniel T. Hartnett
	  	
		 		  	 Helen M. Hartnett
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Daniel T. Hartnett
	  	
		 		  	 /s/ Helen M. Hartnett
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Ryland H. Hubbard, Jr. | Kelly M. Hubbard
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Ryland H. Hubbard, Jr. /s/ Kelly M. Hubbard
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Hyde Family Trust, A
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ R Reid Hyde
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 R Reid Hyde, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Timothy Kasbe
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Timothy Kasbe
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Timothy Kasbe
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	
				
		 	Name:	  	 Joshua and Michelle Kuazban
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Joshua Kuazban
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

							
		 	Name:	  	 John LaGratta
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ John LaGratta
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Thomas Levine
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Thomas Levine
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Victor A. Mangello
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Victor A. Mangello
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Marc Mazur
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Marc Mazur
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 John and Donna MacPhee
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ John MacPhee /s/ Donna MacPhee
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Michael R. McAllister
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Michael R. McAllister
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Marvin H. McIntyre
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Marvin H. McIntyre
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

							
		 	Name:	  	 Sean E. McCance
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Sean E. McCance
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Gerard McNamara
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Gerard McNamara
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Mintz & Co.
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Lowell A. Mintz
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Lowell A. Mintz, Sr. Partner
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Joakim Noah
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Joakim Noah
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Terrence M O’Grady
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Terrence M O’Grady
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Morgan Stanley Cust FBO Robert R Parr
	  	
		 		  	 Robert R. Parr
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Robert M. Parr /s/ Laura Johnson Dearth 2/17/13
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Robert M. Parr - Owner
	  	
		 		  	 Laura Johnson Dearth
	  	
		 		  	 Complex Services Manager
	  	
		 		  	 Washington, DC
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

							
		 	Name:	  	 Richard R. Redmond
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Richard R. Redmond
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Sands Partnership #1
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ A. Baron Cass III
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 A. Baron Cass III, Partner
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Sands Partnership Money Purchase Pension Trust
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ A. Baron Cass III
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 A. Baron Cass III, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Alicia Scott
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Alicia Scott
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Gavin A. Scotti
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Gavin A. Scotti
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Gavin A. Scotti
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Raymond Scott
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Raymond Scott
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Smokeshire Partners, LLC
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Lowell A. Mintz
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Mintz & Co., its Manager by Lowell A. Mintz
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

							
		 	Name:	  	 Squaretop Partners, L.P.
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Wallace L. Hall, Jr.
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

									
		 	Name & Title:	 	By:	 	 Whitehall Management, LLC
	  	
		 		 	 a Texas limited liability company, its General Partner
	  	
		 		 	By:	 	 Wallace L. Hall, Jr., President
	  	
		 		 	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Christina W. Vest and John A. Vest
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Christina W. Vest /s/ John A. Vest
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Louis Viaden
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Louis Viaden
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Weaver Family 2004 Dynasty Trust
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Christina W. Vest
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Christina W. Vest, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Weaver Fund LP
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Christina W. Vest
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Christina W. Vest, GP
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Gaines Wehrle
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Gaines Wehrle
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Gaines Wehrle
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

							
		 	Name:	  	 Michael H. Wehrle
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Michael H. Wehrle
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 John Anthony Weierbach II
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ John A. Weierbach II
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 John A. Weierbach II
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 White Rock Capital Partners III, L.P.
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

											
		 	Signature:	 	by:	 	 White Rock Capital Management, L.P. (Gen Ptnr)
	  	
		 		 	By:	 	 White Rock Capital, Inc. (Gen. Ptnr)
	  	
		 		 	 /s/ Thomas U. Barton
	  	
		 		 	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Thomas U. Barton, President
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Laurence Zalk
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Laurence Zalk
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Meryl Zises 2010 Trust
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Nancy Zises, Trustee
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	 Nancy Zises, Trustee
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

  

							
		 	Name:	  	 Selig Zises
	  	
		 		  	Please print full name of Subscriber (individual or entity)	  	
		 		  	* Please indicate if Subscriber is a trust or if the Shares will be held jointly	  	

  

							
		 	Signature:	  	 /s/ Selig Zises
	  	
		 		  	Authorized signature(s) of Subscriber	  	

  

							
		 	Name & Title:	  	  
	  	
		 		  	Please print name & title of authorized signatory if Subscriber is an entity	  	

			
	Accepted and agreed:
	
	COMPANY:
	
	INTREXON CORPORATION
		
	By:	 	 /s/ Donald P. Lehr

	Name:	 	 Donald P. Lehr

	Title:	 	 Chief Legal OfficerExhibit 10.3

 Exhibit 10.3 
 EXECUTION VERSION 
 CONFIDENTIAL 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act
of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

EXCLUSIVE CHANNEL PARTNER AGREEMENT 

THIS EXCLUSIVE CHANNEL PARTNER
AGREEMENT (the “Agreement”) is made and entered into effective as of January 6, 2011 (the “Effective Date”) by and between INTREXON
CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ZIOPHARM ONCOLOGY, INC., a Delaware
corporation having its principal place of business at 1180 Avenue of the Americas, 19th Floor, New York, NY 10036 (“ZIOPHARM”). Intrexon and ZIOPHARM may be referred to herein individually as a “Party”, and collectively as the “Parties.”

 RECITALS 
 WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the design and production of DNA vectors or their in vivo expression; and

 WHEREAS, ZIOPHARM now desires to become Intrexon’s exclusive channel partner with respect to such
technology for the purpose of developing the Cancer Program (as defined herein), and Intrexon is willing to appoint ZIOPHARM as a channel partner in such field under the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained herein,
the Parties agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 As used in this Agreement, the following
capitalized terms shall have the following meanings: 
 1.1 “Affiliate” means, with respect to a
particular Party, any other person or entity that directly or indirectly controls, is controlled by, or is in common control with such Party. As used in this Section 1.1, the term “controls” (with correlative meanings for the terms
“controlled by” and “under common control with”) means the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of an entity, or the possession, directly or
indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by contract, or otherwise. Notwithstanding the foregoing, except as set forth in Section 2.3(a), Third Security
shall be deemed not to be an Affiliate of Intrexon, and any other person, corporation, partnership, or other entity that would be an Affiliate of Intrexon solely because it and Intrexon are under common control by Randal J. Kirk or by investment
funds managed by Third Security or an affiliate of Third Security shall also be deemed not to be an Affiliate of Intrexon. 

1.2 “Allowable Expenses” means any of the following expenses incurred by ZIOPHARM or an Affiliate of ZIOPHARM
after the First Commercial Sale in the Territory of a ZIOPHARM Product, in each case to the extent specifically attributable to such ZIOPHARM 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Product and specifically attributable to the Commercialization of such ZIOPHARM Product: (a) Cost of Goods Sold, (b) Marketing Expenses, (c) Distribution Expenses,
(d) Post-Launch Product R&D Expenses, and (e) Additional Commercialization Expenses, in each case as such terms are defined and calculated in this Article 1 and in Exhibit A. 

1.3 “Applicable Laws” has the meaning set forth in Section 8.2(d)(xiii). 

1.4 “Authorizations” has the meaning set forth in Section 8.2(d)(xiii). 

1.5 “Blocking Third Party IP” has the meaning set forth in Section 3.7(a). 

1.6 “Cancer Program” has the meaning set forth in Section 2.1. 

1.7 “CC” has the meaning set forth in Section 2.2(b). 

1.8 “Channel-Related Program IP” has the meaning set forth in Section 6.1(c). 

1.9 “Claims” has the meaning set forth in Section 9.1. 

1.10 “CMCC” has the meaning set forth in Section 2.2(b). 

1.11 “Committees” has the meaning set forth in Section 2.2(a). 

1.12 “Commercialize” or “Commercialization” means any activities directed to marketing,
promoting, distributing, importing for sale, offering to sell and/or selling ZIOPHARM Products. 
 1.13
“Confidential Information” means each Party’s confidential information, inventions, non-public know-how or non-public data disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties and
shall include, without limitation, manufacturing, marketing, financial, personnel and other business information and plans, whether in oral, written, graphic or electronic form. 

1.14 “Control” means, with respect to a Patent or other intellectual property right, that a Party owns or has a
license to such right and has the ability to grant a license or sublicense as provided for in this Agreement under such right without violating the terms of any agreement or other arrangement with any Third Party. 

1.15 “CRC” has the meaning set forth in Section 2.2(b). 

1.16 “Diligent Efforts” means, with respect to a Party’s obligation under this Agreement, the level of
efforts and resources reasonably required to diligently develop, manufacture, and/or commercialize (as applicable) a ZIOPHARM Product in a sustained manner, consistent with the efforts and resources a similarly situated company working in the Field
would typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based on market conditions then prevailing. With respect to 

  
 2 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
a particular task or obligation, Diligent Efforts requires that the applicable Party promptly assign responsibility for such task and consistently make and implement decisions and allocate
resources designed to advance progress with respect to such task or obligation. 
 1.17 “Equity
Agreements” has the meaning set forth in Section 5.1. 
 1.18 “Excess Product Liability
Costs” has the meaning set forth in Section 9.3. 
 1.19 “Executive Officer” means the
Chief Executive Officer of the applicable Party, or another senior executive officer of such Party who has been duly appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (a) a
Committee dispute, provided that such officer is not a member of the applicable Committee and occupies a position senior to the positions occupied by the applicable Party’s members of the applicable Committee, or (b) a dispute described in
Section 11.1. 
 1.20 “Existing Cancer Programs” has the meaning set forth in Section 2.1.

 1.21 “FDA” has the meaning set forth in Section 8.2(d)(xiii). 

1.22 “Field Infringement” has the meaning set forth in Section 6.3(b) 

1.23 “Field” means the use of DNA administered to humans for expression of anti-cancer effectors for the purpose
of treatment or prophylaxis of cancer; provided, however, that the Field does not include any therapies or other medical interventions that are directed toward the treatment or prophylaxis of a non-cancer disease or condition (e.g., infectious
disease) unless the primary reason for such treatment or prophylaxis is to prevent cancer. For the avoidance of doubt, the Field excludes (a) the treatment or prophylaxis of cancer in non-human animals and (b) the amelioration of symptoms
or complications of cancer, including side effects of other cancer treatments (as opposed to the treatment of the cancer itself). 
 1.24 “First Commercial Sale” means, with respect to a ZIOPHARM Product and country, the first sale to a Third Party of such ZIOPHARM Product in such country after regulatory
approval (and any pricing or reimbursement approvals, if necessary) has been obtained in such country. 
 1.25
“Fully Loaded Cost” means the direct cost of the applicable good, product or service plus indirect charges and overheads reasonably allocable to the provision of such good, product or service in accordance with US GAAP.

 1.26 “Information” means information, results and data of any type whatsoever, in any tangible or
intangible form whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological,
chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions. 

  
 3 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.27 “Infringement” has the meaning set forth in
Section 6.3(a). 
 1.28 “Intrexon Channel Technology” means Intrexon’s technology directed
towards in vivo expression of effectors, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP. 
 1.29 “Intrexon Indemnitees” has the meaning set forth in Section 9.2. 
 1.30 “Intrexon IP” means the Intrexon Patents and Intrexon Know-How. 
 1.31 “Intrexon Know-How” means all Information (other than Intrexon Patents) that (a) is Controlled by Intrexon as of the Effective Date or during the Term and (b) is
reasonably required or useful for ZIOPHARM to conduct the Cancer Program. For the avoidance of doubt, the Intrexon Know-How shall include any Information (other than Intrexon Patents) in the Channel-Related Program IP. 

1.32 “Intrexon Materials” means the genetic code and associated gene constructs used alone or in combination and
such other proprietary reagents including but not limited to plasmid vectors, virus stocks, and cells and cell lines (e.g., natural killer cells and dendritic cells), in each case that are reasonably required or provided to ZIOPHARM to conduct the
Cancer Program. 
 1.33 “Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as
of the Effective Date or during the Term; and (b) are reasonably required or useful for ZIOPHARM to conduct the Cancer Program. For the avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP.

 1.34 “Intrexon Trademarks” means those trademarks related to the Intrexon Channel Technology that are
established from time to time by Intrexon for use across its channel partnerships. 
 1.35 “Inventions”
has the meaning set forth in Section 6.1(b). 
 1.36 “IPC” has the meaning set forth in
Section 2.2(b). 
 1.37 “JSC” has the meaning set forth in Section 2.2(b). 

1.38 “Losses” has the meaning set forth in Section 9.1. 

1.39 “Net Sales” means, with respect to any ZIOPHARM Product, the net sales of such ZIOPHARM Product by ZIOPHARM or an
Affiliate of ZIOPHARM (including without limitation net sales of ZIOPHARM Product to a non-Affiliate sublicensee but not including net sales by such non-Affiliate sublicensee), as determined in accordance with US GAAP. 

1.40 “Patents” means (a) all patents and patent applications (including provisional applications),
(b) any substitutions, divisions, continuations, continuations-in-part, reissues, 

  
 4 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
renewals, registrations, requests for continued examination, confirmations, re-examinations, extensions, supplementary protection certificates and the like of the foregoing, and (c) any
foreign or international equivalents of any of the foregoing. 
 1.41 “Product Profit” means Net Sales
less Allowable Expenses. 
 1.42 “Product-Specific Program Patent” means any issued Intrexon Patent
where all the claims are directed to Inventions that relate solely and specifically to ZIOPHARM Products. In the event of a disagreement between the Parties as to whether a particular Intrexon Patent is or is not a Product-Specific Program Patent,
the Parties shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to arbitration pursuant to Section 11.2. Any Intrexon Patent that is
subject to such a dispute shall be deemed not to be a Product-Specific Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program Patent or (b) an arbitrator or arbitration panel
determines, pursuant to Article 11, that such Intrexon Patent is a Product-Specific Program Patent. 
 1.43
“Proposed Terms” has the meaning set forth in Section 11.2. 
 1.44 “Prosecuting
Party” has the meaning set forth in Section 6.2(c). 
 1.45 “Recovery” has the meaning set
forth in Section 6.3(f). 
 1.46 “Required Third Party IP” has the meaning set forth in
Section 3.7(a). 
 1.47 “Retained Product” has the meaning set forth in Section 10.4(a).

 1.48 “Reverted Product” has the meaning set forth in Section 10.4(c). 

1.49 “SEC” means the United States Securities and Exchange Commission. 

1.50 “Sublicensing Revenue” means any cash consideration (including upfront payments, milestone payments, and
royalties), and the cash equivalent of all other consideration, actually received by ZIOPHARM or its Affiliate from a Third Party in consideration for a grant of a sublicense under the Intrexon IP or any rights to develop or commercialize ZIOPHARM
Products, but excluding: (a) any amounts paid as bona fide reimbursement for research and development costs to the extent incurred following such grant; (b) bona fide loans or any payments in consideration for a grant of equity of ZIOPHARM
to the extent that such consideration is equal to or less than fair market value (i.e. any amounts in excess of fair market value shall be Sublicensing Revenue); or (c) amounts received from sublicensees in respect of any ZIOPHARM Product sales
that are included in Net Sales. 
 1.51 “Superior Therapy” means a cancer therapy in the Field that,
based on the data then available, (a) demonstrably appears to offer superior efficacy, safety or cost, as compared with both (i) those therapies that are marketed (either by ZIOPHARM or others) at such time for a given cancer indication
and (ii) those therapies that are being actively developed by 

  
 5 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
ZIOPHARM for such cancer indication; (b) demonstrably appears to represent a substantial improvement over such existing therapies; and (c) has intellectual property protection and a
regulatory approval pathway that, in each case, would not present a significant barrier to commercial development. 
 1.52
“Support Memorandum” has the meaning set forth in Section 11.2. 
 1.53 “Third
Party” means any individual or entity other than the Parties or their respective Affiliates. 
 1.54
“Third Party IP” has the meaning set forth in Section 3.7(a). 
 1.55 “Third
Security” means Third Security, LLC. 
 1.56 “Territory” means the entire world. 

1.57 “US GAAP” means generally accepted accounting principles in the United States. 

1.58 “Working Group” has the meaning set forth in Section 2.3(d). 

1.59 “ZIOPHARM Indemnitees” has the meaning set forth in Section 9.1. 

1.60 “ZIOPHARM Product” means any product in the Field that is created, produced, developed, or identified
directly or indirectly by or on behalf of ZIOPHARM during the term of this Agreement, whether through use or practice of Intrexon Channel Technology or the Intrexon Materials or otherwise, including, without limitation, any products that are the
subject of the Existing Cancer Programs. 
 1.61 “ZIOPHARM Program Patent” has the meaning set forth in
Section 6.2(b). 
 1.62 “ZIOPHARM Termination IP” means all Patents or other intellectual property
that ZIOPHARM or any of its Affiliates Controls as of the Effective Date or during the Term that Cover, or is otherwise necessary or useful for, the development, manufacture or commercialization of a Reverted Product or necessary or useful for
Intrexon to operate in the Field. 
 ARTICLE 2 
 SCOPE OF CHANNEL PARTNERSHIP; MANAGEMENT 
 2.1 General. The general purpose of the channel partnership described in this Agreement will be to use the Intrexon Channel Technology (a) in connection with the following currently existing
Intrexon programs in the Field: DC-RTS IL-12 Phase Ib clinical cancer program (IND #13565) and the AdV RTS-IL-12 cancer program (the “Existing Cancer Programs”) and (b) generally to research, develop and commercialize products
for use in the 

  
 6 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Field (collectively, the “Cancer Program”). As provided below, the JSC shall establish projects for the Cancer Program. Either Party may propose potential projects in the Field
for review and consideration by the JSC. 
 2.2 Committees. 

(a) Generally. The Parties desire to establish several committees (collectively, “Committees”) to oversee the
Cancer Program and to facilitate communications between the Parties with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have the obligation to
exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. 
 (b) Formation and Purpose. Promptly following the Effective Date, the Parties shall create the Committees listed in the chart below, each of which shall have the purpose indicated in the chart.

  

			
	 Committee
	  	 Purpose

		
	Joint Steering Committee (“JSC”)	  	Establish projects for the Cancer Program and establish the priorities for such projects.
		
	Chemistry, Manufacturing and Controls Committee (“CMCC”)	  	Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Cancer Program.
		
	Clinical/Regulatory Committee (“CRC”)	  	Review and approve all research and development plans, clinical projects and publications, and regulatory filings and correspondence under the Cancer Program; review and approve
itemized budgets with respect to the foregoing.
		
	Commercialization Committee (“CC”)	  	Establish project plans and review and approve activities and budgets for commercialization activities under the Cancer Program.
		
	Intellectual Property Committee (“IPC”)	  	Evaluate intellectual property issues in connection with the Cancer Program; review and approve itemized budgets with respect to the foregoing.

  
 7 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 2.3 General Committee Membership and Procedure. 

(a) Membership. For each Committee, each Party shall designate an equal number of representatives who are employees of such Party
or an Affiliate of such Party (not to exceed three (3) for each Party) with appropriate expertise to serve as members of such Committee (and Third Security shall be deemed to be an Affiliate of Intrexon solely for purposes of this
Section 2.3). Each representative may serve on more than one Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any time upon written notice to the other Party. Each
Committee shall have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative to the Committee will act as chairperson shall alternate between the Parties, with ZIOPHARM
selecting the chairperson first for the JSC, CRC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of each Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance
of each meeting of such Committee, and preparing and issuing minutes of each meeting within thirty (30) days thereafter. 

(b) Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held
less frequently than once every six (6) months. Meetings of any Committee may be held in person or by means of telecommunication (telephone, video, or web conferences). To the extent that a Committee holds any meetings in person, the Parties
will alternate in designating the location for such in-person meetings, with ZIOPHARM selecting the first meeting location for each Committee. A reasonable number of additional representatives of a Party may attend meetings of a Committee in a
non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any Committee (including without limitation in any Working Group). 
 (c) Meeting Agendas. Each Party will disclose to the other proposed agenda items along with appropriate information at least seven (7) business days in advance of each meeting of the
applicable Committee; provided, that a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other
Party consents to such later addition of such agenda items or the absence of a specific agenda for such Committee meeting. 

(d) Working Groups. From time to time, each Committee may establish and delegate duties to other committees, sub-committees or
directed teams (each, a “Working Group”) on an “as-needed” basis to oversee particular projects or activities. Each such Working Group shall be constituted and shall operate as the applicable Committee determines;
provided, that each Working Group shall have equal representation from each Party. Each Working Group and its activities shall be subject to the oversight, review and approval of, and shall report to, the Committee that established such Working
Group. In no event shall the authority of the Working Group exceed that specified for the relevant Committee in this Article 2. 

(e) Limitations of Committee Powers. Each Committee shall have only such powers as are specifically delegated to it hereunder or
from time to time as agreed to by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without 

  
 8 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
limiting the generality of the foregoing, no Committee shall have any power to amend this Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to
Section 12.7 below. 
 2.4 Committee Decision-Making. If a Committee is unable to reach unanimous consent on a
particular matter within thirty (30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute to the Executive Officer of the other Party. The Executive Officers of each of the Parties will
meet at least once in person or by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to resolve the dispute within thirty (30) days after submission of such dispute to the
Executive Officers. If any such dispute is not resolved by the Executive Officers within thirty (30) days after submission of such dispute to such officers, then the Executive Officer of the Party specified in the applicable subsection below
shall have the authority to finally resolve such dispute acting in good faith. 
 (a) Casting Vote at JSC. If a dispute
at the JSC is not resolved pursuant to Section 2.4 above, then the Executive Officer of ZIOPHARM shall have the authority to finally resolve such dispute 
 (b) Casting Vote at CMCC. If a dispute at the CMCC is not resolved pursuant to Section 2.4 above, then (i) in the case of any disputes relating to the Intrexon Materials, the manufacture
of a ZIOPHARM Product active pharmaceutical ingredient, or the manufacturing of other components of ZIOPHARM Products contracted for or manufactured by Intrexon, the Executive Officer of Intrexon shall have the authority to finally resolve such
dispute; and (ii) in the case of any other disputes, the Executive Officer of ZIOPHARM shall have the authority to finally resolve such dispute. 
 (c) Casting Vote at CRC. If a dispute at the CRC is not resolved pursuant to Section 2.4 above, then the Executive Officer of ZIOPHARM shall have the authority to finally resolve such dispute.

 (d) Casting Vote at CC. If a dispute at the CC is not resolved pursuant to Section 2.4 above, then the Executive
Officer of ZIOPHARM shall have the authority to finally resolve such dispute. 
 (e) Casting Vote at IPC. If a dispute at
the IPC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the Parties with respect to Product-Specific
Program Patents (i.e. neither Party shall have the casting vote on such matters, and any such disputes shall be resolved pursuant to Article 11). 
 (f) Other Committees. If any additional Committee is formed, then the Parties shall, at the time of such formation, agree on which Party shall have the authority to finally resolve a dispute that
is not resolved pursuant to Section 2.4 above. 

  
 9 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (g) Restrictions. Neither Party shall exercise its right to finally resolve a
dispute at a committee in accordance with this Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement; (ii) expands the obligations of the other Party under this
Agreement; (iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute involving the breach or alleged breach of this Agreement; (v) resolves a
matter if the provisions of this Agreement specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is inconsistent with applicable law. 

ARTICLE 3 

LICENSE GRANTS 
 3.1 Licenses to ZIOPHARM. 
 (a) Subject to the terms and conditions
of this Agreement, Intrexon hereby grants to ZIOPHARM a license under the Intrexon IP to research, develop, use, import, make, have made, sell, and offer for sale ZIOPHARM Products in the Field in the Territory. Such license shall be exclusive (even
as to Intrexon) with respect to any clinical development, selling, offering for sale or other Commercialization of ZIOPHARM Products in the Field, and shall be otherwise non-exclusive. 

(b) Subject to the terms and conditions of this Agreement, Intrexon hereby grants to ZIOPHARM a non-exclusive, royalty-free
license to use and display the Intrexon Trademarks, solely in connection with the Commercialization of ZIOPHARM Products, in the promotional materials, packaging, and labeling for ZIOPHARM Products, as provided under and in accordance with
Section 4.9. 
 3.2 Sublicensing. Except as provided below, ZIOPHARM shall not sublicense the rights granted under
Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or commercialize ZIOPHARM Products, in each case except with Intrexon’s written
consent, which written consent may be withheld in Intrexon’s sole discretion. Notwithstanding the foregoing, ZIOPHARM may transfer, to the extent reasonably necessary, Intrexon Materials to a Third Party contractor performing post-API
fill/finish responsibilities for ZIOPHARM Products, and may grant any sublicenses necessary to enable such Third Party to perform such activities. In addition, ZIOPHARM shall not sublicense the rights granted under Section 3.1 to an Affiliate,
or transfer the Intrexon Materials to any Affiliate, or otherwise grant any Affiliate the right to research, develop, use, or commercialize ZIOPHARM Products, in each case except with Intrexon’s written consent, which written consent shall not
be unreasonably withheld or delayed. In the event that Intrexon consents to any such grant or transfer to an Affiliate, ZIOPHARM shall remain responsible for, and be guarantor of, the performance by any such Affiliate and shall cause such Affiliate
to comply with the provisions of this Agreement in connection with such performance (as though such Affiliate were ZIOPHARM), including any payment obligations owed to Intrexon hereunder. None of the enforcement rights under the Intrexon Patents
that are 

  
 10 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
granted to ZIOPHARM pursuant to Section 6.3 shall be transferred to, or exercised by, a sublicensee except with Intrexon’s prior written consent, which may be withheld in
Intrexon’s sole discretion. 
 3.3 No Non-Permitted Use. ZIOPHARM hereby covenants that it shall not, nor shall it
permit any Affiliate or, if applicable, (sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those expressly permitted by this Agreement.

 3.4 Exclusivity. Intrexon and ZIOPHARM mutually agree that, under the channel partnership established by this
Agreement, it is intended that the Parties will be exclusive to each other in the Field. To this end, neither Intrexon nor its Affiliates shall make the Intrexon Channel Technology or Intrexon Materials available to any Third Party for the purpose
of developing or commercializing products in the Field, and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third Party or Affiliate) the research, development or commercialization of any product for purpose of sale in
the Field, outside of the Cancer Program. Further, neither ZIOPHARM nor its Affiliates shall pursue (either by itself or with a Third Party or Affiliate) the research, development or commercialization of any product for purpose of sale in the Field,
outside of the Cancer Program. 
 3.5 Off Label Use. For purpose of clarity, (a) following the First Commercial Sale
of a ZIOPHARM Product, the use by direct or indirect purchasers or other users of ZIOPHARM Products outside the Field (i.e. “off label use”) shall not constitute a breach by ZIOPHARM of the terms of Section 3.3 or 3.4, provided that
neither ZIOPHARM nor its Affiliate (nor any Third Party under contract with either of them) marketed or promoted ZIOPHARM Products for such off-label use; and (b) following the first commercial sale of a product by Intrexon, an Intrexon
Affiliate, or a Third Party sublicensee, collaborator, or partner of Intrexon, the use by direct or indirect purchasers or other users of such products in the Field (i.e. “off label use”) shall not constitute a breach by Intrexon of the
terms of Section 3.4, provided that neither Intrexon nor its Affiliate (nor any Third Party under contract with either of them) marketed or promoted such products for such off-label use. 

3.6 No Prohibition on Intrexon. Except as explicitly set forth in Sections 3.1 and 3.4, nothing in this Agreement shall prevent
Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing, ZIOPHARM acknowledges
that Intrexon has all rights, in Intrexon’s sole discretion, to make the Intrexon Materials, Intrexon Channel Technology (including any active pharmaceutical ingredient used in a ZIOPHARM Product), and Intrexon IP available to Third Party
channel partners for use in fields outside the Field. 
 3.7 Third Party Licenses. 

(a) [*****] shall obtain [*****] any licenses from Third Parties that are required in order to practice the Intrexon Channel
Technology in the Field where the licensed 

  
 11 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
intellectual property is directed to Intrexon’s in vivo expression system or the specific effector molecule used in the Existing Cancer Programs as of the Effective Date (but
excluding intellectual property directed to any other specific effector molecules) (“Required Third Party IP”). Other than with respect to Required Third Party IP, [*****] shall be solely responsible for obtaining [*****] any
licenses from Third Parties that [*****] determines, in its sole discretion, are required in order to lawfully make, use, sell, offer for sale, or import ZIOPHARM Products (“Blocking Third Party IP”). Required Third Party IP and
Blocking Third Party IP are collectively referred to as “Third Party IP”). 
 (b) In the event that
either Party desires to license from a Third Party any Required Third Party IP or Blocking Third Party IP, such Party shall so notify the other Party in writing, and the IPC shall discuss such Third Party IP and its applicability to the ZIOPHARM
Products and to the Field. As provided above in Section 3.7(a), [*****] shall have the sole right and responsibility to pursue a license under Required Third Party IP, and [*****] hereby covenants that it shall not itself directly license such
Required Third Party IP at any time, provided that [*****] may (but shall not be obligated to) obtain such a license directly if the Third Party owner or licensee of such Required Third Party IP brings an infringement action against
[*****] or its Affiliates and, after written notice to [*****] of such action, [*****] fails to obtain a license to such Required Third Party IP within ninety (90) days after such notice. Following the IPC’s discussion of any Blocking
Third Party IP, subject to Section 3.7(c), [*****] shall have the right to pursue a license under Blocking Third Party IP [*****]. For the avoidance of doubt, [*****] may at any time obtain a license under Blocking Third Party IP outside the
Field [*****] provided that if [*****] decides to seek to obtain such a license, it shall use reasonable efforts to coordinate its licensing activities in this regard with [*****]. 

(c) [*****] shall provide the proposed terms of any license under Blocking Third Party IP and the final version of the definitive
license agreement for any Blocking Third Party IP to the IPC for review and discussion prior to signing, and shall consider [*****] comments thereto in good faith. To the extent that [*****] obtains a license under Required Third Party IP, [*****]
shall provide the final version of the definitive license agreement for such Required Third Party IP to the IPC. If [*****] acquires rights under any Third Party IP outside the Field, it will do so on a non-exclusive basis unless it obtains the
prior written consent of [*****] for such license outside the Field to be exclusive. Any Party that is pursuing a license to any Third Party IP with respect to the Field under this Section 3.7 shall keep the other Party reasonably informed of
the status of any negotiations relating thereto. For purposes of clarity, (i) any costs incurred by [*****] in obtaining and maintaining licenses to Required Third Party IP shall be borne solely by [*****] and shall not be included as an
Allowable Expense, and (ii) any costs incurred by [*****] in obtaining and maintaining licenses to Blocking Third Party IP (and, to the limited extent provided in subsection (b), Required Third Party IP) shall be treated as [*****]. 

(d) For any Third Party license under which ZIOPHARM or its Affiliates obtain a license under Patents claiming inventions or
know-how specific to or used or incorporated into the development, manufacture, and/or commercialization of ZIOPHARM Products, ZIOPHARM shall use commercially reasonable efforts to ensure that ZIOPHARM will have the ability, pursuant to
Section 10.4(h), to assign such agreement to Intrexon or grant a sublicense to Intrexon thereunder (having the scope set forth in Section 10.4(h)). 

  
 12 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (e) The licenses granted to ZIOPHARM under Section 3.1 may include
sublicenses under Intrexon IP that has been licensed to Intrexon by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable upstream license agreement, subject to the cost allocation set
forth in Section 3.7(c), provided that Intrexon shall either provide unredacted copies of such upstream license agreements to ZIOPHARM or shall disclose in writing to ZIOPHARM all of such terms and conditions that are applicable
to ZIOPHARM. ZIOPHARM shall not be responsible for complying with any provisions of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to ZIOPHARM as provided in the preceding sentence. 

3.8 Licenses to Intrexon. Subject to the terms and conditions of this Agreement, ZIOPHARM hereby grants to Intrexon a
non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by ZIOPHARM or its Affiliates, solely to the extent necessary for Intrexon to conduct those responsibilities assigned
to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any of Intrexon’s subcontractors. 
 3.9 Restrictions Relating to Intrexon Materials. ZIOPHARM shall use the Intrexon Materials solely for purposes of the Cancer Program and not for any other purpose without the prior written consent
of Intrexon. With respect to the Intrexon Materials comprising Intrexon’s vector assembly technology, ZIOPHARM shall not, and shall ensure that ZIOPHARM personnel do not (a) distribute, sell, lend or otherwise transfer such Intrexon
Materials to any Third Party; (b) co-mingle such Intrexon Materials with any other proprietary biological or chemical materials without Intrexon’s written consent; or (c) analyze such Intrexon Materials or in any way attempt to
reverse engineer or sequence such Intrexon Materials. 
 ARTICLE 4 

OTHER RIGHTS AND OBLIGATIONS 

4.1 Development and Commercialization. Subject to Sections 4.6 and 4.7, ZIOPHARM shall be solely responsible for the performance
of the Cancer Program and the development and commercialization of ZIOPHARM Products in the Field. ZIOPHARM shall be responsible for all costs incurred in connection with the Cancer Program except that Intrexon shall be responsible for the
following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs,
through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing ZIOPHARM Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of
non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of discovery-stage research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) (but, for clarity,
excluding 

  
 13 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
research described in Section 4.7); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above
shall include the scale-up of Intrexon Materials and API for clinical trials and commercialization of ZIOPHARM Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts
internally or through Third Party contractors retained by either Intrexon or ZIOPHARM (with Intrexon’s consent). 
 4.2
Transfer of Existing Cancer Programs. Promptly following the Effective Date, Intrexon shall promptly assign to ZIOPHARM, and will provide full copies of, all regulatory approvals and regulatory filings that relate to the Existing Cancer
Programs. Intrexon shall also (a) make available to ZIOPHARM all Intrexon Materials associated with the conduct of the Existing Cancer Programs, and (b) take such actions and execute such other instruments, assignments and documents as may
be necessary to effect the transfer of rights thereunder to ZIOPHARM. No later than sixty (60) days after the Effective Date (or as soon thereafter as practicable), Intrexon shall provide to ZIOPHARM copies of the relevant portions of all
material reports and data, including clinical and non-clinical data and reports, obtained or generated by or on behalf of Intrexon or its Affiliates in connection with the Existing Cancer Programs. Thereafter, as additional projects are included in
the Cancer Program, the JSC shall develop a plan and protocol for each such project relating to the transfer of relevant data and Intrexon Materials. 
 4.3 Information and Reporting. ZIOPHARM will keep Intrexon informed about ZIOPHARM’s efforts to develop and commercialize ZIOPHARM Products, including reasonable and accurate summaries of
ZIOPHARM’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any
material deviations, and significant developments in the development and/or commercialization of the ZIOPHARM Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt
of a response to such United States or international regulatory filing, clinical safety event, receipt of Regulatory Approval, or commercial launch. Intrexon will keep ZIOPHARM informed about Intrexon’s efforts (a) to establish
manufacturing capabilities and facilities for ZIOPHARM Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the
Cancer Program with respect to the Intrexon Channel Technology and Intrexon Materials. Such disclosures by ZIOPHARM and Intrexon will be made in the course of JSC meetings at least once every six (6) months while ZIOPHARM Products are being
developed or commercialized anywhere in the world, and shall be reflected in the minutes of such meetings. 
 4.4 Regulatory
Matters. At all times after the Effective Date, ZIOPHARM shall own and maintain, at its own cost, all regulatory filings and Regulatory Approvals for ZIOPHARM Products that ZIOPHARM is developing or Commercializing pursuant to this Agreement. As
such, ZIOPHARM shall be responsible for reporting all adverse events related to such ZIOPHARM Products to the appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such countries. The
decision to list or not 

  
 14 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
list Patents in any regulatory filing for a ZIOPHARM Product (for example, as required by 21 C.F.R. § 314.53(b)), or add or delete a Patent from a regulatory filing shall be determined by
Intrexon, after consultation with ZIOPHARM, except with respect to Product Specific Program Patents, which will be mutually determined by the Parties. 
 4.5 Diligence. 
 (a) ZIOPHARM shall use Diligent Efforts to develop
and commercialize ZIOPHARM Products. 
 (b) Without limiting the generality of the foregoing, Intrexon may, from time to
time, notify ZIOPHARM that it believes it has identified a Superior Therapy, and in such case shall provide to ZIOPHARM its then-available information about such therapy. ZIOPHARM shall have the following obligations with respect to such proposed
Superior Therapy: (i) within sixty (60) days after such notification, ZIOPHARM shall prepare and deliver to the JSC for review and approval a development plan detailing how ZIOPHARM will pursue the Superior Therapy (including a proposed
budget); (ii) ZIOPHARM shall revise the development plan as directed by the JSC; and (iii) following approval of the development plan by the JSC, ZIOPHARM shall use Diligent Efforts to pursue the development of the Superior Therapy under
the Cancer Program in accordance with such development plan. If ZIOPHARM fails to comply with the foregoing obligations, or if ZIOPHARM exercises its casting vote at the JSC to either (x) prevent the approval of a development plan for a
Superior Therapy; (y) delay such approval more than sixty (60) days after delivery of the development plan to the JSC; or (z) approve a development plan that is insufficient in view of the nature and magnitude of the opportunity
presented by the Superior Therapy, then Intrexon shall have the termination right set forth in Section 10.2(b) (subject to the limitation set forth therein). For clarity, any dispute arising under this 4.5, including any dispute as to whether a
proposed project constitutes a Superior Therapy (as with any other dispute under this Agreement) shall be subject to dispute resolution in accordance with Article 11. 
 (c) The activities of ZIOPHARM’s Affiliates and any permitted sublicensees shall be attributed to ZIOPHARM for the purposes of evaluating ZIOPHARM’s fulfillment of the obligations set
forth in this Section 4.5. 
 4.6 Manufacturing. Intrexon shall use Diligent Efforts to perform any manufacturing
activities in connection with the Cancer Program that relate to the Intrexon Materials, the manufacture of bulk drug product, the manufacturing of bulk quantities of other components of ZIOPHARM Products, or any earlier steps in the manufacturing
process for ZIOPHARM Products. Except as provided in Section 4.1, any manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in
connection with such manufacturing, on terms to be negotiated by the Parties in good faith. In the event that Intrexon does not manufacture Intrexon Materials, bulk drug product or bulk qualities of other components of ZIOPHARM Products, then
Intrexon shall provide to ZIOPHARM or a contract manufacturer selected by ZIOPHARM and approved by Intrexon all Information Controlled by Intrexon that is related to the 

  
 15 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
manufacturing of such Intrexon Materials, bulk drug product or bulk qualities of other components of ZIOPHARM Products, for use in the Field and is reasonably necessary to enable ZIOPHARM or such
contract manufacturer (as appropriate) for the sole purpose of manufacturing such Intrexon Materials, bulk drug product or bulk quantities of other components of ZIOPHARM Products, in each case as manufactured by Intrexon. The costs and expenses
incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any manufacturing Information transferred hereunder to ZIOPHARM or its contract manufacturer shall not be further transferred to any Third Party or ZIOPHARM Affiliate
without the prior written consent of Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if necessary to permit ZIOPHARM to switch manufacturers. 

4.7 Support Services. From time to time, on an ongoing basis, ZIOPHARM shall request, or Intrexon may propose, that Intrexon
perform certain support services with respect to the Cancer Program, such services including but not limited to, pre-clinical or clinical activities relating to transition of the Cancer Program to ZIOPHARM. To the extent that the Parties mutually
agree that Intrexon should perform such services, the Parties shall negotiate in good faith the terms under which services would be performed, it being understood that Intrexon would be compensated for such services by cash payments equal to
Intrexon’s Fully Loaded Cost in connection with such services. 
 4.8 Compliance with Law. Each Party shall comply,
and shall ensure that its Affiliates, (sub)licensees and Third Party contractors comply, with all applicable laws, regulations, and guidelines applicable to the Cancer Program, including without limitation those relating to the transport, storage,
and handling of Intrexon Materials and ZIOPHARM Products. 
 4.9 Trademarks. To the extent permitted by applicable law
and regulations, ZIOPHARM shall, and shall ensure that the packaging, promotional materials, and labeling for ZIOPHARM Products shall carry, in a conspicuous location, the applicable Intrexon Trademark(s), subject to ZIOPHARM’s reasonable
approval of the size, position, and location thereof. ZIOPHARM shall provide Intrexon with copies of any materials containing the Intrexon Trademarks prior to using or disseminating such materials, in order to obtain ZIOPHARM’s approval
thereof. ZIOPHARM’s use of the Intrexon Trademarks shall be subject to prior review and approval of the IPC. ZIOPHARM acknowledges Intrexon’s sole ownership of the Intrexon Trademarks and agrees not to take any action inconsistent with
such ownership. ZIOPHARM covenants that it shall not use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any ZIOPHARM Product). From time to time during the Term, Intrexon shall have the right
to obtain from ZIOPHARM samples of ZIOPHARM Product sold by ZIOPHARM or its Affiliates or sublicensees for the purpose of inspecting the quality of such ZIOPHARM Products and use of the Intrexon Trademark(s). In the event that Intrexon inspects the
quality of such ZIOPHARM Products and use of the Intrexon Trademark, Intrexon shall notify the result of such inspection to ZIOPHARM in writing thereafter. ZIOPHARM shall comply with reasonable policies provided by Intrexon from time-to-time to
maintain the goodwill and value of the Intrexon Trademarks. 

  
 16 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 5 
 COMPENSATION 
 5.1 Equity. In partial consideration
for ZIOPHARM’s appointment as an exclusive channel partner and the other rights granted to ZIOPHARM hereunder, ZIOPHARM has agreed to issue to Intrexon certain shares of ZIOPHARM’s common stock, in accordance with the terms and conditions
of that certain Stock Purchase Agreement and Registration Rights Agreement, each of even date herewith (the “Equity Agreements”). Pursuant to the Equity Agreements, Intrexon has also agreed to purchase certain shares of the
Company’s common stock for cash consideration, subject to the terms and conditions therein. Provided that all closing conditions for the First Tranche Closing (as defined in the Equity Agreements) that are within the reasonable control of
Intrexon have been satisfied or waived, the issuance of the First Tranche Shares (as defined in the Equity Agreements) is a condition subsequent to the effectiveness of this Agreement. 

5.2 Profit-Share. 
 (a) No later than thirty (30) days after each calendar quarter in which there is positive Product Profit arising from the sale of ZIOPHARM Product in the Field in the Territory, ZIOPHARM shall
pay to Intrexon fifty percent (50%) of such Product Profit, on a ZIOPHARM Product-by-ZIOPHARM Product basis. In the event of negative Product Profit for a particular ZIOPHARM Product in any calendar quarter, neither ZIOPHARM nor Intrexon shall
owe any payments hereunder with respect to such ZIOPHARM Product. Any negative Product Profit that results from Excess Product Liability Costs, and Third Party Blocking IP Costs (as defined in Exhibit A) may be carried forward to future quarters and
offset against positive Product Profit in such future quarters for the same ZIOPHARM Product. Except as set forth in the preceding sentence, ZIOPHARM shall not be permitted to carry forward any negative Product Profits to subsequent quarters.

 (b) No later than thirty (30) days after each calendar quarter in which ZIOPHARM or any ZIOPHARM Affiliate
receives Sublicensing Revenue, ZIOPHARM shall pay to Intrexon fifty percent (50%) of such Sublicensing Revenue. As set forth in Section 3.2, sublicensing shall require Intrexon’s prior written consent. Nevertheless, this
Section 5.2(b) shall apply to Sublicensing Revenue received by ZIOPHARM or any ZIOPHARM Affiliate, even if rights were granted to the applicable sublicensee in violation of this Agreement. For purposes of clarity, sales of ZIOPHARM Products by
approved sublicensees shall not constitute Net Sales. 
 5.3 Method of Payment. All payments due to Intrexon under this
Agreement shall be paid in United States dollars by wire transfer to a bank in the United States designated in writing by Intrexon. All references to “dollars” or “$” herein shall refer to United States dollars. 

5.4 Payment Reports and Records Retention. Within thirty (30) days after the end of each calendar quarter during which Net
Sales have been generated or Allowable Expenses been incurred, ZIOPHARM shall deliver to Intrexon a written report that shall contain at a minimum for the applicable calendar quarter: 

  
 17 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (a) gross sales of each ZIOPHARM Product (on a country-by-country basis);

 (b) itemized calculation of Net Sales, showing all applicable deductions; 

(c) itemized calculation of Allowable Expenses and Sublicensing Revenue; 

(d) the amount of the payment (if any) due pursuant to Section 5.2(a) and/or 5.2(b); 

(e) the amount of taxes, if any, withheld to comply with any applicable law; and 

(f) the exchange rates used in any of the foregoing calculations. 
 For three (3) years after each sale of ZIOPHARM Product or the incurring of an item included in Allowable Expenses, ZIOPHARM shall keep (and shall ensure that its Affiliates and, if applicable,
(sub)licensees shall keep) complete and accurate records of such sales or Allowable Expenses (as the case may be) in sufficient detail to confirm the accuracy of the payment calculations hereunder. 

5.5 Audits. 
 (a) Upon the written request of Intrexon, ZIOPHARM shall permit an independent certified public accounting firm of internationally recognized standing selected by Intrexon, and reasonably
acceptable to ZIOPHARM, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written notice, the applicable records of ZIOPHARM and its Affiliates to verify the accuracy and timeliness of
the reports and payments made by ZIOPHARM under this Agreement. Such review may cover the records for sales made in any calendar year ending not more than three (3) years prior to the date of such request. The accounting firm shall disclose to
both Parties whether the royalty reports and/or know-how reports conform to the provisions of this Agreement and/or US GAAP, as applicable, and the specific details concerning any discrepancies. Such audit may not be conducted more than once in
any calendar year. 
 (b) If such accounting firm concludes that additional amounts were owed during such period,
ZIOPHARM shall pay additional amounts, with interest from the date originally due as set forth in Section 5.7, within thirty (30) days of receipt of the accounting firm’s written report. If the amount of the underpayment is greater
than five percent (5%) of the total amount actually owed for the period audited, then ZIOPHARM shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon shall pay all costs of the audit. In the event of
overpayment, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar quarter(s); provided, however, that such credit cannot be applied to reduce the amounts payable by ZIOPHARM to
Intrexon for any particular calendar quarter by more than twenty-five percent (25%) of the amount otherwise due to Intrexon. 

  
 18 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) Intrexon shall (i) treat all information that it receives under this
Section 5.5 in accordance with the confidentiality provisions of Article 7 and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with ZIOPHARM obligating such firm to retain all such financial information
in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for Intrexon to enforce its rights under this Agreement. 
 5.6 Taxes. The Parties will cooperate in good faith to obtain the benefit of any relevant tax treaties to minimize as far as reasonably possible any taxes which may be levied on any amounts payable
hereunder. ZIOPHARM shall deduct or withhold from any payments any taxes that it is required by applicable law to deduct or withhold. Notwithstanding the foregoing, if Intrexon is entitled under any applicable tax treaty to a reduction of the rate
of, or the elimination of, applicable withholding tax, it may deliver to ZIOPHARM or the appropriate governmental authority (with the assistance of ZIOPHARM to the extent that this is reasonably required and is expressly requested in writing) the
prescribed forms necessary to reduce the applicable rate of withholding or to relieve ZIOPHARM of its obligation to withhold tax, and ZIOPHARM shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be,
provided that ZIOPHARM has received evidence of Intrexon’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the payment is due.
If, in accordance with the foregoing, ZIOPHARM withholds any amount, it shall make timely payment to the proper taxing authority of the withheld amount, and send to Intrexon proof of such payment within forty-five (45) days following that
latter payment. 
 5.7 Late Payments. Any amount owed by ZIOPHARM to Intrexon under this Agreement that is not paid
within the applicable time period set forth herein shall accrue interest at the lower of (a) two percent (2%) per month, compounded, or (b) the highest rate permitted under applicable law. 

ARTICLE 6 

INTELLECTUAL PROPERTY 
 6.1 Ownership. 
 (a) Subject to the license granted under
Section 3.1, all rights in the Intrexon IP shall remain with Intrexon. 
 (b) ZIOPHARM and/or Intrexon may solely or
jointly conceive, reduce to practice or develop discoveries, inventions, processes, techniques, and other technology, whether or not patentable, in the course of performing the Cancer Program (collectively “Inventions”). Each Party
shall promptly provide the other Party with a detailed written description of any such Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws. 

  
 19 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) Intrexon shall solely own all right, title and interest in all Inventions
related to Intrexon Channel Technology, together with all Patent rights and other intellectual property rights therein (the “Channel-Related Program IP”). ZIOPHARM hereby assigns all of its right, title and interest in and to the
Channel-Related Program IP to Intrexon. ZIOPHARM agrees to execute such documents and perform such other acts as Intrexon may reasonably request to obtain, perfect and enforce its rights to the Channel-Related Program IP and the assignment thereof.

 (d) Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or other
technology, whether or not patentable, that is conceived, reduced to practice or developed by ZIOPHARM solely or jointly through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and conditions of
this Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Intrexon and shall be included in the Channel-Related Program IP. 

(e) All information regarding Channel-Related Program IP shall be Confidential Information of Intrexon. ZIOPHARM shall be under
appropriate written agreements with each of its employees or agents working on the Cancer Program, pursuant to which such person shall grant all rights in the Inventions to ZIOPHARM (so that ZIOPHARM may convey certain of such rights to Intrexon, as
provided herein). 
 6.2 Patent Prosecution. 
 (a) Intrexon shall have the sole right, but not the obligation, to conduct and control the filing, prosecution and maintenance of the Intrexon Patents. At the reasonable request of Intrexon,
ZIOPHARM shall cooperate with Intrexon in connection with such filing, prosecution, and maintenance, at Intrexon’s expense. Under no circumstances shall ZIOPHARM (a) file, attempt to file, or assist anyone else in filing, or attempting to
file, any Patent application, either in the United States or elsewhere, that claims or uses or purports to claim or use or relies for support upon an Invention owned by Intrexon or use, attempt to use, or assist anyone else in using or attempting to
use, the Intrexon Know-How, Intrexon Materials, or any Confidential Information of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to the Intrexon IP, Intrexon
Materials, or the Intrexon Channel Technology. 
 (b) ZIOPHARM shall have the sole right, but not the obligation, to
conduct and control the filing, prosecution and maintenance of any Patents claiming Inventions that are owned by ZIOPHARM or its Affiliates and not assigned to Intrexon under Section 6.1(c) ( “ZIOPHARM Program Patents”). At the
reasonable request of ZIOPHARM, Intrexon shall cooperate with ZIOPHARM in connection with such filing, prosecution, and maintenance, at ZIOPHARM’s expense. 

  
 20 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) The Prosecuting Party shall be entitled to use patent counsel selected by it
and reasonably acceptable to the non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the prosecution of the Intrexon Patents and ZIOPHARM Program Patents, as applicable. The Prosecuting Party shall:

 (i) regularly provide the other Party in advance with reasonable information relating to the Prosecuting Party’s
prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings and correspondence that the Prosecuting
Party proposes to submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible to the public, the Prosecuting Party may, in lieu of directly providing copies of such information to such
other Party, provide such other Party with sufficient information that will permit such other Party to access such information itself directly); 
 (ii) consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; provided, however, that if, within fifteen (15) days after providing any
documents to the non-Prosecuting Party for comment, the Prosecuting Party does not receive any written communication from the non-Prosecuting Party indicating that it has or may have comments on such document, the Prosecuting Party shall be entitled
to assume that the non-Prosecuting Party has no comments thereon; 
 (iii) consult with the non-Prosecuting Party before taking
any action that would reasonably be expected to have a material adverse impact on the scope of claims within the Intrexon Patents and ZIOPHARM Program Patents, as applicable. 
 As used above “Prosecuting Party” means Intrexon in the case of Intrexon Patents and ZIOPHARM in the case of ZIOPHARM Program Patents. 

6.3 Infringement of Patents by Third Parties. 
 (a) Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to take appropriate action against any person or entity directly or indirectly
infringing any Intrexon Patent (or asserting that a Intrexon Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or lawsuit or other appropriate action. 

(b) Notwithstanding the foregoing, ZIOPHARM shall have the first right, but not the obligation, to take appropriate action to
enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (“Field Infringement”), either by settlement or lawsuit or other
appropriate action. If ZIOPHARM fails to take the appropriate steps to enforce Product-Specific Program Patents against any Field Infringement within one hundred eighty (180) days of the date one Party has provided notice to the other Party
pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall have the right (but not the obligation), at its own expense, to enforce Product-Specific Program Patents against such Field Infringement, either by settlement or lawsuit
or other appropriate action. 

  
 21 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) With respect to any Field Infringement that cannot reasonably be abated
through the enforcement of Product-Specific Program Patents pursuant to Section 6.3(b) but can reasonable be abated through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be obligated to
choose one of the following courses of action: (i) enforce one or more of the applicable Intrexon Patent(s) in a commercially reasonable manner against such Field Infringement, or (ii) [*****]. Intrexon and ZIOPHARM shall bear the costs
and expenses of such enforcement equally. The determination of which Intrexon Patent(s) to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult in good faith with ZIOPHARM on such determination. For
the avoidance of doubt, Intrexon has no obligations under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement. 

(d) In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably cooperate with the
enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the enforcing Party’s expense (except with respect to an action under Section 6.3(c), where all costs and expenses
will be shared equally in accordance with terms thereof). 
 (e) ZIOPHARM shall not settle or otherwise compromise any
action under this Section 6.3 in a way that diminishes the rights or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written consent, which consent shall not be unreasonably
withheld. Intrexon shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or interests of ZIOPHARM in the Field or adversely affects any Intrexon Patent with respect to the Field without
ZIOPHARM’s prior written consent, which consent shall not be unreasonably withheld. 
 (f) Except as otherwise
agreed to by the Parties in writing, any settlements, damages or other monetary awards recovered pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party
controlling such action, and second, to the costs and expenses (if any) of the other Party (to the extent not otherwise reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows: In any action
initiated by Intrexon pursuant to Section 6.3(a) that does not involve Field Infringement, or in any action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery. In any
action initiated by ZIOPHARM pursuant to Section 6.3(b), ZIOPHARM shall retain one hundred percent (100%) of any Recovery, but such Recovery shall be shared with Intrexon as Sublicensing Revenue. In any action initiated by Intrexon or
ZIOPHARM pursuant to Section 6.3(c), the Parties shall share the Recovery equally, and such Recovery shall not be deemed to constitute Sublicensing Revenue. 
 (g) ZIOPHARM shall promptly notify Intrexon in writing of any alleged, threatened, or actual Infringement of which it becomes aware, and Intrexon shall promptly notify ZIOPHARM in writing of any
alleged, threatened, or actual Field Infringement of which it becomes aware. 

  
 22 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 7 
 CONFIDENTIALITY 
 7.1 Confidentiality. Except to the
extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for
in this Agreement any Confidential Information disclosed to it by the other Party pursuant to this Agreement, except to the extent that the receiving Party can demonstrate by competent evidence that specific Confidential Information: 

(a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the
other Party; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its
disclosure to the receiving Party; 
 (c) became generally available to the public or otherwise part of the public domain
after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d)
was disclosed to the receiving Party, other than under an obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or 

(e) was independently discovered or developed by the receiving Party without the use of Confidential Information belonging to the
disclosing Party, as documented by the receiving Party’s written records. 
 The foregoing non-use and non-disclosure
obligation shall continue (i) indefinitely, for all Confidential Information that qualifies as a trade secret under applicable law; or (ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases.

 7.2 Authorized Disclosure. Notwithstanding the limitations in this Article 7, either Party may disclose the
Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 
 (a) complying with applicable laws or regulations or valid court orders, provided that the Party making such disclosure provides the other Party with reasonable prior written notice of such
disclosure and makes a reasonable effort to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the terms and conditions of this Agreement be used only for the purposes
for which the law or regulation required, or for which the order was issued; 

  
 23 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (b) to regulatory authorities in order to seek or obtain approval to conduct
clinical trials, or to gain regulatory approval, of ZIOPHARM Products or any products being developed by Intrexon or its other licensees and/or channel partners, provided that the Party making such disclosure (i) provides the other Party with
reasonable opportunity to review any such disclosure in advance and to suggest redactions or other means of limiting the disclosure of such other Party’s Confidential Information and (ii) does not unreasonably reject any such suggestions;

 (c) disclosure to investors and potential investors, acquirers, or merger candidates who agree to maintain the
confidentiality of such information, provided that such disclosure is used solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be); 

(d) disclosure on a need-to-know basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such as CROs and
clinical investigators) who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7; and 
 (e) disclosure of the terms of this Agreement by Intrexon to collaborators and other channel partners who agree to be bound by obligations of confidentiality and non-use at least equivalent in
scope to those set forth in this Article 7. 
 7.3 Publicity. The Parties agree that the public announcement of the
execution of this Agreement shall be substantially in the form of the press release attached as Exhibit B. 
 7.4 Terms of
the Agreement. Each Party shall treat the terms of this Agreement as the Confidential Information of other Party, subject to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that the other
Party may be obligated to file a copy of this Agreement with the SEC, either as of the Effective Date or at some point during the Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of
certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available to it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement
marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party’s comments thereon to the extent consistent with the legal requirements governing
redaction of information from material agreements that must be publicly filed. The other Party shall promptly provide any such comments. 
 7.5 Proprietary Information Audits. 
 (a) For the purpose of
confirming compliance with the Field-limited licenses granted in Article 3 and the confidentiality obligations under Article 7, ZIOPHARM acknowledges that Intrexon’s authorized representative(s), during regular business hours may
(i) examine and inspect ZIOPHARM’s facilities and (ii) inspect all data and work products relating to this Agreement. Any examination or inspection hereunder shall require five (5) business days

  
 24 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
written notice from Intrexon to ZIOPHARM. ZIOPHARM will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance
review. 
 (b) In view of the Intrexon Confidential Information, Intrexon Know-How, and Intrexon Materials transferred to
ZIOPHARM hereunder, Intrexon from time-to-time, but no more than quarterly, may request that ZIOPHARM confirm the status of the Intrexon Materials at Company (i.e. how much used, how much shipped, to whom and any unused amounts destroyed (by whom,
when) as well as any amounts returned to Intrexon or destroyed). Within ten (10) business days of ZIOPHARM’s receipt of any such written request, ZIOPHARM shall provide the written report to Intrexon. 

7.6 Intrexon Commitment. Intrexon shall use reasonable efforts to obtain an agreement with its other licensees and channel
partners to enable ZIOPHARM to disclose confidential information of such licensees and channel partners to regulatory authorities in order to seek or obtain approval to conduct clinical trials, or to gain regulatory approval of, ZIOPHARM Products,
in a manner consistent with the provisions of Section 7.2(b). 
 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1 Representations and Warranties of ZIOPHARM. ZIOPHARM hereby represents and warrants to Intrexon that, as of the Effective
Date: 
 (a) Corporate Power. ZIOPHARM is duly organized and validly existing under the laws of Delaware and has corporate
full power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization.
ZIOPHARM is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on ZIOPHARM’s behalf has been duly authorized to do so by all requisite corporate action.

 (c) Binding Agreement. This Agreement is a legal and valid obligation binding upon ZIOPHARM and enforceable in
accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to general equity principles and
to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by ZIOPHARM does not conflict with any agreement, instrument or understanding, oral or written, to which it
is a party or by which it may be bound. ZIOPHARM is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement. 

  
 25 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 8.2 Representations and Warranties of Intrexon. Intrexon hereby represents and
warrants to ZIOPHARM that, as of the Effective Date: 
 (a) Corporate Power. Intrexon is duly organized and validly
existing under the laws of Virginia and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization. Intrexon is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Intrexon’s behalf
has been duly authorized to do so by all requisite corporate action. 
 (c) Binding Agreement. This Agreement is a legal
and valid obligation binding upon Intrexon and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting
creditors’ rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the
validity of this Agreement. 
 (d) Additional Intellectual Property Representations. 

(i) Intrexon possesses sufficient rights to enable Intrexon to grant all rights and licenses it purports to grant to ZIOPHARM with
respect to the Intrexon Patents under this Agreement; 
 (ii) The Intrexon Patents existing as of the Effective Date constitute
all of the Patents Controlled by Intrexon as of such date that are necessary for the development, manufacture or Commercialization of ZIOPHARM Products; 
 (iii) Intrexon has not granted, and during the Term Intrexon will not grant, any right or license, to any Third Party under the Intrexon IP that conflicts with the rights or licenses granted or to be
granted to ZIOPHARM hereunder; 
 (iv) There is no pending litigation, and Intrexon has not received any written notice of any
claims or litigation, seeking to invalidate or otherwise challenge the Intrexon Patents or Intrexon’s rights therein; 

(v) To Intrexon’s knowledge, except as otherwise disclosed to ZIOPHARM prior to the Effective Date, the use of the Intrexon
Materials in connection with the Existing Cancer Programs as of the Effective Date and the conduct of the Existing Cancer Programs as contemplated as of the Effective Date, does not (A) infringe any claims of any Patents of any Third Party, or
(b) misappropriate any Information of any Third Party; 

  
 26 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (vi) None of the Intrexon Patents is subject to any pending re-examination, opposition,
interference or litigation proceedings; 
 (vii) All of the Intrexon Patents have been filed and prosecuted in accordance with
all applicable laws and have been maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid; 
 (viii) Intrexon has entered into agreements with each of its current and former officers, employees and consultants involved in research and development work, including development of the Intrexon’s
products and technology providing Intrexon, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other
of such persons, during the period of employment by Intrexon (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to ZIOPHARM herein), and Intrexon is not aware that any of
its employees or consultants is in material violation thereof; 
 (ix) To Intrexon’s knowledge, there is no infringement,
misappropriation or violation by third parties of any Intrexon Channel Technology in the Field; 
 (x) There is no pending or,
to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others against Intrexon that Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with
the use of the Intrexon Channel Technology, and Intrexon has not received any written notice of such claim; 
 (xi) To
Intrexon’s knowledge, no employee of Intrexon is the subject of any claim or proceeding involving a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,
non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer (A) where the basis of such violation relates to such employee’s employment with Intrexon or actions undertaken by the employee
while employed with Intrexon and (B) where such violation is relevant to the use of the Intrexon Channel Technology in the Field; 
 (xii) None of the Intrexon Patents owned by Intrexon or its Affiliates, and, to Intrexon’s knowledge, the Intrexon Patents licensed to Intrexon or its Affiliates, have been adjudged invalid or
unenforceable by a court of competent jurisdiction or applicable government agency, in whole or in part, and there is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or
scope of any such Intrexon Patents; and 
 (xiii) Except as otherwise disclosed in writing to ZIOPHARM, Intrexon: (A) is
in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or
disposal of any product that is under 

  
 27 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
development, manufactured or distributed by Intrexon in the Field (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter,
untitled letter or other correspondence or notice from the United States Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material
noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which would not,
individually or in the aggregate, result in a material adverse effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such Authorizations are valid and in full force and
effect and Intrexon is not in material violation of any term of any such Authorizations; and (D) since January 1, 2008, (1) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or
Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit investigation or proceeding;
(2) has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has
no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated,
conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product
defect or violation and, to Intrexon’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action. Except to the extent disclosed in writing to ZIOPHARM, since January 1, 2008, Intrexon has not
received any notices or correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical
trials conducted by or on behalf of Intrexon. 
 except, in each of (ix) through (xiii), for any instances which would not, individually or
in the aggregate, result in a material adverse effect on the rights granted to ZIOPHARM hereunder or Intrexon’s ability to perform its obligations hereunder. 
 8.3 Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS ARTICLE 8 OR IN THE EQUITY AGREEMENTS, EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR
IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

  
 28 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 9 
 INDEMNIFICATION 
 9.1 Indemnification by Intrexon.
Intrexon agrees to indemnify, hold harmless, and defend ZIOPHARM and its Affiliates and their respective directors, officers, employees, and agents (collectively, the “ZIOPHARM Indemnitees”) from and against any and all liabilities,
damages, costs, expenses, or losses (including reasonable legal expenses and attorneys’ fees) (collectively, “Losses”) resulting from any claims, suits, actions, demands, or other proceedings brought by a Third Party
(collectively, “Claims”) to the extent arising from (a) the gross negligence or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents, (b) the use, handling, storage or transport
of Intrexon Materials by or on behalf of Intrexon or its Affiliates, licensees (other than ZIOPHARM) or sublicensees; or (c) breach by Intrexon of any representation, warranty or covenant in this Agreement. Notwithstanding the foregoing,
Intrexon shall not have any obligation to indemnify the ZIOPHARM Indemnitees to the extent that a Claim arises from (i) the gross negligence or willful misconduct of ZIOPHARM or any of its Affiliates, licensees, or sublicensees, or their
respective employees or agents; or (ii) a breach by ZIOPHARM of a representation, warranty, or covenant of this Agreement. 

9.2 Indemnification by ZIOPHARM. ZIOPHARM agrees to indemnify, hold harmless, and defend Intrexon, its Affiliates and Third
Security, and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to Intrexon intellectual property rights within Intrexon IP on or prior to the Effective Date, to the extent required by the
relevant upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses resulting from Claims, to the extent arising from any of the following: (a) the gross negligence or willful misconduct
of ZIOPHARM or any of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of Intrexon Materials by or on behalf of ZIOPHARM or its Affiliates, licensees, or sublicensees; (c) breach by
ZIOPHARM or any representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture, regulatory approval, handling, storage, transport, distribution, sale or other disposition of any ZIOPHARM Product by or on
behalf of ZIOPHARM or its Affiliates, licensees, or sublicensees. Notwithstanding the foregoing, ZIOPHARM shall not have any obligation to indemnify the Intrexon Indemnitees to the extent that a Claim arises from (i) the gross negligence or
willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents; or (ii) a breach by Intrexon of a representation, warranty, or covenant of this Agreement. 

9.3 Product Liability Claims. Notwithstanding the provisions of Section 9.2, any Losses arising out of any Third Party claim,
suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the development, manufacture or commercialization of any ZIOPHARM Products for use or sale in

  
 29 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
the Field, to the extent that such Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance (“Excess Product Liability Costs”), shall
be paid by [*****] and shared by the Parties as Allowable Expenses for purposes of calculating Cumulative Product Profit, except to the extent such Losses arise out of any Third-Party Claim based on the gross negligence or willful misconduct of a
Party, its Affiliates, its or its Affiliates’ Sublicensees, or any of the respective officers, directors, employees and agents of each of the foregoing entities, in the performance of obligations or exercise of rights under this Agreement.

 9.4 Control of Defense. As a condition precedent to any indemnification obligations hereunder, any entity entitled to
indemnification under this Article 9 shall give written notice to the indemnifying Party of any Claims that may be subject to indemnification, promptly after learning of such Claim. If such Claim falls within the scope of the indemnification
obligations of this Article 9, then the indemnifying Party shall assume the defense of such Claim with counsel reasonably satisfactory to the indemnified Party. The indemnified Party shall cooperate with the indemnifying Party in such defense. The
indemnified Party may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to such Claim. The indemnifying Party shall not be liable for any litigation costs or expenses incurred by the
indemnified Party without the indemnifying Party’s written consent, such consent not to be unreasonably withheld. The indemnifying Party shall not settle any such Claim if such settlement (a) does not fully and unconditionally release the
indemnified Party from all liability relating thereto or (b) adversely impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified Party otherwise agrees in writing. 

9.5 Insurance. During the term of this Agreement, ZIOPHARM shall maintain in effect and good standing a product liability
insurance policy issued by a reputable insurance company in amounts considered standard for the industry. At Intrexon’s reasonable request, ZIOPHARM shall provide Intrexon with all details regarding such policy, including without limitation
copies of the applicable liability insurance contracts. ZIOPHARM shall use reasonable efforts to include Intrexon as an additional insured on any such policy. 
 ARTICLE 10 
 TERM; TERMINATION

 10.1 Term. The term of this Agreement shall commence upon the Effective Date and shall continue until terminated
pursuant to Section 10.2 or 10.3. 
 10.2 Termination for Material Breach; Termination Under Section 4.5(b)

 (a) Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the
other Party commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the nonbreaching Party specifying such breach. 

  
 30 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (b) Intrexon shall have the right to terminate this Agreement under the
circumstances set forth in Section 4.5(b) upon written notice to ZIOPHARM, such termination to become effective sixty (60) days following such written notice unless ZIOPHARM remedies the circumstances giving rise to such termination within
such sixty (60) day period. 
 (c) Intrexon shall have the right to terminate this Agreement under the circumstances
set forth in Section 12.8 upon written notice to ZIOPHARM, such termination to become effective immediately upon such written notice. 
 (d) Notwithstanding the foregoing, during the twenty-four (24) month period commencing on the Effective Date, neither Party shall have the right to terminate this Agreement under
Section 10.2(a) based on the failure of the other Party to use Diligent Efforts or to comply with any other diligence obligations hereunder (including Section 4.5), nor shall Intrexon have the right to terminate this Agreement under
Section 4.5(b). 
 10.3 Termination by ZIOPHARM. ZIOPHARM shall have the right to voluntarily terminate this
Agreement in its entirety upon ninety (90) days written notice to Intrexon at any time, provided that such notice may not be given during the twenty four (24) month period commencing on the Effective Date. 

10.4 Effect of Termination. In the event of termination of this Agreement pursuant to Section 10.2 or Section 10.3, the
following shall apply: 
 (a) Retained Products. ZIOPHARM shall be permitted to continue the development and
commercialization of any ZIOPHARM Product that, at the time of termination, satisfies at least one of the following criteria (a “Retained Product”): 
 (i) is being Commercialized by ZIOPHARM, 
 (ii) has received regulatory approval,

 (iii) is a subject of an application for regulatory approval in the Field that is pending before the applicable regulatory
authority, or 
 (iv) is the subject of at least 
 (A) an ongoing Phase 2 clinical trial in the Field (in the case of a termination by Intrexon due to a ZIOPHARM uncured breach pursuant to Section 10.2(a) or a termination by ZIOPHARM pursuant to
Section 10.3), or 
 (B) an ongoing Phase 1 clinical trial in the Field (in the case of a termination by ZIOPHARM due to
an Intrexon uncured breach pursuant to Section 10.2(a) or a termination by Intrexon pursuant to Section 10.2(b) or 10.2(c)). 

  
 31 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 Such right to continue development and commercialization shall be subject to ZIOPHARM’s full
compliance with the payment provisions in Article 5 and all other provisions of this Agreement that survive termination. 

(b) Termination of Licenses. Except as necessary for ZIOPHARM to continue to develop and commercialize the Retained Products as
permitted by Section 10.4(a), all rights and licenses granted by Intrexon to ZIOPHARM under this Agreement shall terminate and shall revert to Intrexon without further action by either Intrexon or ZIOPHARM. ZIOPHARM’s license with respect
to Retained Products shall be exclusive or non-exclusive, as the case may be, on the same terms as set forth in Section 3.1. 
 (c) Reverted Products. All ZIOPHARM Products other than the Retained Products shall be referred to herein as the “Reverted Products.” ZIOPHARM shall immediately cease, and shall
cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and commercialization of the Reverted Products, and ZIOPHARM shall not use or practice, nor shall it cause or permit any of its Affiliates or, if
applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the Reverted Products. ZIOPHARM shall immediately discontinue making any representation regarding its status as a licensee or channel partner of
Intrexon with respect to the Reverted Products. 
 (d) Intrexon Materials. ZIOPHARM shall promptly return, or at
Intrexon’s request, destroy, any Intrexon Materials in ZIOPHARM’s possession or control at the time of termination, or other than any Intrexon Materials necessary for the continued development and commercialization of the Retained
Products. 
 (e) Licenses to Intrexon. ZIOPHARM is automatically deemed to grant to Intrexon a worldwide, fully paid,
royalty-free, exclusive (even as to ZIOPHARM and its Affiliates), irrevocable, license (with full rights to sublicense) under the ZIOPHARM Termination IP, to make, have made, import, use, offer for sale and sell Reverted Products and to use the
Intrexon Channel Technology, the Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive rights held by ZIOPHARM in Reverted Products pursuant to Section 10.4(c). ZIOPHARM shall also take such actions and execute such
other instruments and documents as may be necessary to document such license to Intrexon. 
 (f) Regulatory Filings.
ZIOPHARM shall promptly assign to Intrexon, and will provide full copies of, all regulatory approvals and regulatory filings that relate specifically and solely to Reverted Products. ZIOPHARM shall also take such actions and execute such other
instruments, assignments and documents as may be necessary to effect the transfer of rights thereunder to Intrexon. To the extent that there exist any regulatory approvals and regulatory filings that relate both to Reverted Products and other
products, ZIOPHARM shall provide copies of the portions of such regulatory filings that relate to Reverted Products and shall reasonably cooperate to assist Intrexon in obtaining the benefits of such regulatory approvals with respect to the Reverted
Products. 

  
 32 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (g) Data Disclosure. ZIOPHARM shall provide to Intrexon copies of the relevant
portions of all material reports and data, including clinical and non-clinical data and reports, obtained or generated by or on behalf of ZIOPHARM or its Affiliates to the extent that they relate to Reverted Products, within sixty (60) days of
such termination unless otherwise agreed, and Intrexon shall have the right to use any such Information in developing and commercializing Reverted Products and to license any Third Parties to do so. 

(h) Third-Party Licenses. At Intrexon’s request, ZIOPHARM shall promptly provide to Intrexon copies of all Third-Party
agreements under which ZIOPHARM or its Affiliates obtained a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture and/or commercialization of the Reverted Products. At
Intrexon’s request, ZIOPHARM shall promptly: (x) with respect to such Third Party licenses relating solely to the applicable Reverted Products, immediately assign (or cause to be assigned), such agreements to Intrexon, and (y) with
respect to all other Third Party licenses, at ZIOPHARM’s option either assign the agreement or grant (or cause to be granted) to Intrexon a sublicense thereunder of a scope equivalent to that described in Section 10.4(e), provided ZIOPHARM
has the ability to assign such agreement to Intrexon or grant a sublicense to Intrexon thereunder. In any case, thereafter Intrexon shall be fully responsible for all obligations due for its actions under the Third Party agreements. Notwithstanding
the above, if Intrexon does not wish to assume any financial or other obligations associated with a particular assignment or sublicense, then Intrexon shall so notify ZIOPHARM and ZIOPHARM shall not make such assignment or grant such sublicense (or
cause it to be made or granted). 
 (i) Remaining Materials. At the request of Intrexon, ZIOPHARM shall transfer to
Intrexon, all quantities of Reverted Product (including API or work-in-process) in the possession of ZIOPHARM or its Affiliates. ZIOPHARM shall transfer to Intrexon all such quantities of Reverted Products without charge, except that Intrexon shall
pay the reasonable costs of shipping. 
 (j) Third Party Vendors. At Intrexon’s request, ZIOPHARM shall promptly
provide to Intrexon copies of all agreements between ZIOPHARM or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply, sale, or distribution of Reverted Products in the Territory. At Intrexon’s request,
ZIOPHARM shall promptly: (x) with respect to such Third Party agreements relating solely to the applicable Reverted Products, immediately assign (or cause to be assigned), such agreements to Intrexon, and (y) with respect to all other such
Third Party agreements, ZIOPHARM shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. ZIOPHARM shall be liable for any costs associated with assigning a Third Party agreement to Intrexon or otherwise obtaining
the benefits of such agreement for Intrexon, to the extent such costs are directly related to ZIOPHARM’s breach. For the avoidance of doubt, Intrexon shall have no obligation to assume any of ZIOPHARM’s obligations under any Third Party
agreement. 
 (k) Commercialization. Intrexon shall have the right to develop and commercialize the Reverted Products
itself or with one or more Third Parties, and shall have the right, without obligation to ZIOPHARM, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate. 

  
 33 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (l) Confidential Information. Each Party shall promptly return, or at the other
Party’s request destroy, any Confidential Information of the other Party in such Party’s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain (i) a single copy of each item
of Confidential Information of the other Party in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party that is maintained as archive copies
on the recipient Party’s disaster recovery and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s rights in Retained Products (in the case of ZIOPHARM) or
Reverted Products (in the case of Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information retained in accordance with this
Section 10.4(l). 
 10.5 Surviving Obligations. Termination or expiration of this Agreement shall not affect any
rights of either Party arising out of any event or occurrence prior to termination, including, without limitation, any obligation of ZIOPHARM to pay any amount which became due and payable under the terms and conditions of this Agreement prior to
expiration or such termination. The following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 5.5, 5.7, 6.1, 6.2 (with subsection (c) surviving only to the extent relating to Intrexon Patents that
are relevant to Retained Products that, to Intrexon’s knowledge, are being developed or commercialized at such time, if any), 10.4, and 10.5; Articles 7, 9, 11, and 12; and any relevant definitions in Article 1. 

ARTICLE 11 

DISPUTE RESOLUTION 
 11.1 Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and
without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this Agreement (other than disputes arising from a Committee), including,
without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of either Party by written notice, the Parties agree to meet and
discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting between the Executive Officers of each Party. If the matter is not resolved within thirty (30) days following the written
request for discussions, either Party may then invoke the provisions of Section 11.2. For the avoidance of doubt, any disputes, controversies or differences arising from a Committee pursuant to Article 2 shall be resolved solely in accordance
with Section 2.4. 

  
 34 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 11.2 Arbitration. Any dispute, controversy, difference or claim which may arise
between the Parties and not from a Committee, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach,
performance, application or termination of this Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Section 11.10, be settled by binding “baseball arbitration” as follows. Either Party, following the end of
the thirty (30) day period referenced in Section 11.1, may refer such issue to arbitration by submitting a written notice of such request to the other Party. Promptly following receipt of such notice, the Parties shall meet and discuss in
good faith and seek to agree on an arbitrator to resolve the issue, which arbitrator shall be neutral and independent of both Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering
agreements in the pharmaceutical and biotechnology industries, and shall have some experience in mediating or arbitrating issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request
by a Party for arbitration, then each Party shall select an arbitrator meeting the foregoing criteria and the two (2) arbitrators so selected shall select a third arbitrator meeting the foregoing criteria. Within fifteen (15) days after an
arbitrator(s) is selected (in the case of the three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written proposal setting forth its proposed terms for the
resolution for the matter at issue (the “Proposed Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will also provide the arbitrator(s) a copy of this Agreement, as it
may be amended at such time. Within fifteen (15) days after receipt of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the other Party) a response to the other
Party’s Support Memorandum. Neither Party may have any other communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly permitted in this Section 11.2; provided
that, the arbitrator(s) may convene a hearing if the arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party’s Proposed Terms. Within sixty (60) days after the arbitrator’s
appointment, the arbitrator(s) will select one of the two Proposed Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement. The
decision of the arbitrator(s) shall be final, binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both
Proposed Terms or award any other relief or take any other action. 
 11.3 Governing Law. This Agreement shall be
governed by and construed under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another
jurisdiction. 
 11.4 Award. Any award to be paid by one Party to the other Party as determined by the arbitrator(s) as
set forth above under Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged
against the losing Party. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 

  
 35 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
11, and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16, judgment may be entered upon the final award in any United States District Court located in
New York and that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the date of any damages incurred for breach of the Agreement, and from the date of the award until
paid in full, at a rate fixed by the arbitrator(s). With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s) or any court or any other forum to award consequential, incidental, special, punitive or
exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or exemplary damages. The only damages recoverable under this Agreement are direct compensatory
damages. 
 11.5 Costs. Each Party shall bear its own legal fees. The arbitrator(s) shall assess his or her costs, fees
and expenses against the Party losing the arbitration. 
 11.6 Injunctive Relief. Nothing in this Article 11 will
preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute
either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. Specifically, the Parties agree that a material breach by either Party of its obligations
in 3.4 of this Agreement may cause irreparable harm to the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies otherwise available at law, including, without limitation, the recovery of
damages for breach of this Agreement, upon an adequate showing of material breach of such Section 3.4, and without further proof of irreparable harm other than this acknowledgement, such non-breaching Party shall be entitled to seek
(a) immediate equitable relief, specifically including, but not limited to, both interim and permanent restraining orders and injunctions, and (b) such other and further equitable relief as the court may deem proper under the
circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall otherwise limit a breaching Party’s opportunity to cure a material breach as permitted in accordance with Section 10.2. 

11.7 Confidentiality. The arbitration proceeding shall be confidential and the arbitrator(s) shall issue appropriate protective
orders to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement with respect to the proceedings or decision of the arbitrator(s) without
prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator(s), except as required in connection with the enforcement of such award or
as otherwise required by applicable law. 
 11.8 Survivability. Any duty to arbitrate under this Agreement shall remain
in effect and be enforceable after termination of this Agreement for any reason. 
 11.9 Jurisdiction. For the purposes
of this Article 11, the Parties acknowledge their diversity and agree to accept the jurisdiction of any United States District Court located in New 

  
 36 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
York for the purposes of enforcing or appealing any awards entered pursuant to this Article 11 and for enforcing the agreements reflected in this Article 11 and agree not to commence any action,
suit or proceeding related thereto except in such courts. 
 11.10 Patent Disputes. Notwithstanding any other provisions
of this Article 11, and subject to the provisions of Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Intrexon Patents shall be submitted to a court of competent jurisdiction
in the country in which such Patent was filed or granted. 
 ARTICLE 12 

GENERAL PROVISIONS 
 12.1 Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other or any other trade name or trademark of the other in
connection with the performance of this Agreement. 
 12.2 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE
OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS
PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7. 

12.3 Independent Parties. The Parties are not employees or legal representatives of the other Party for any purpose. Neither Party
shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement shall not constitute, create, or in any way be interpreted as a joint venture, partnership, or business organization of any kind.

 12.4 Notice. All notices, including notices of address change, required or permitted to be given under this Agreement
shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms receipt of such transmission with the other party by telephone), on the
business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage prepaid, return receipt requested. All such communications shall be sent
to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing): 

  
 37 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

			
	If to Intrexon:	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: Legal Department
 Fax: (301) 556-9902

		
	with a copy to:	  	 Cooley LLP
 3175 Hanover
St.
 Palo Alto, CA 94304
 Attention:
Robert Jones
 Fax: (650) 849-7400

		
	If to ZIOPHARM:	  	 ZIOPHARM Oncology, Inc.
 One
First Avenue
 Parris Building, 34
 Navy
Yard Plaza
 Boston, MA 02129

Attention: Chief Executive Officer
 Fax: (617)
241-2855

		
	with a copy to:	  	 WilmerHale
 60 State
Street
 Boston, MA 02109
 Attention:
Stuart Falber
 Fax: (617) 526-5000

 12.5 Severability. In the event any provision of this Agreement is held to be invalid or
unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 
 12.6 Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. 

12.7 Entire Agreement; Amendment. This Agreement and the exhibits attached hereto constitute the entire, final, complete and
exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement (including any prior confidentiality agreement between the Parties). All
information of Intrexon or ZIOPHARM to be kept confidential by the other Party under any prior confidentiality agreement, as of the Effective Date, shall be maintained as Confidential Information by such other Party under the obligations set forth
in Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 
 12.8 Nonassignability; Binding on Successors. Any attempted assignment of the rights or delegation of the obligations under this Agreement shall be void without the prior

  
 38 

 EXECUTION VERSION 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
written consent of the nonassigning or nondelegating Party; provided, however, that either Party may assign its rights or delegate its obligations under this Agreement without such consent
(a) to an Affiliate of such Party or (b) to its successor in interest in connection with any merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets, provided
that such assignee agrees in writing to assume and be bound by the assignor’s obligations under this Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators
and permitted assigns of the Parties hereto. Notwithstanding the foregoing, in the event that either Party assigns this Agreement to its successor in interest by way of merger, acquisition, or sale of all or substantially all of its assets (whether
this Agreement is actually assigned or is assumed by such successor in interest or its affiliate by operation of law (e.g., in the context of a reverse triangular merger)), (a) the intellectual property rights of such successor in interest or
any of its affiliates shall be automatically excluded from the rights licensed to the other Party under this Agreement, and (b) such successor in interest may elect by written notice to have the restrictions set forth in Section 3.4 not
apply to the activities of such successor in interest (but, for purposes of clarity, such restriction shall in any event continue to apply to the applicable Party and all other Affiliates of such Party not related to such successor in interest). In
the event that a successor in interest to ZIOPHARM elects to have the restrictions set forth in Section 3.4 not apply to the activities of such successor in interest, Intrexon shall have the termination right set forth in Section 10.2(c).

 12.9 Force Majeure. Neither Party shall be liable to the other for its failure to perform any of its obligations under
this Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without limitation earthquakes,
governmental regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

12.10 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property,
whether by implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement. 
 12.11
Legal Compliance. The Parties shall review in good faith and cooperate in taking such actions to ensure compliance of this Agreement with all applicable laws. 
 12.12 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall constitute together the same instrument. 

[Remainder of page intentionally left blank.] 

  
 39 

 IN WITNESS WHEREOF, the Parties hereto
have duly executed this Exclusive Channel Partner Agreement. 
  

							
		
	INTREXON CORPORATION	  	ZIOPHARM ONCOLOGY, INC.
				
	By:	 	 /s/ Randal J. Kirk
	  	By:	 	 /s/ Jonathan Lewis

							
				
	Name:	 	 Randal J. Kirk
	  	Name:	 	 Jonathan Lewis

							
				
	Title:	 	 Chief Executive Officer
	  	Title:	 	 Chief Executive Officer

 EXHIBIT A 
 Financial Terms for Calculating Allowable Expenses 
 As used herein, the term
“operating unit” shall mean the smallest operating unit in which an operating profit and loss statement is prepared for management accounting purposes in the applicable Party’s normal accounting procedures, consistently applied within
and across its operating units. To the extent certain cost or expense items below are incurred with respect to multiple products and some of such products are not ZIOPHARM Products, then such cost or expense items shall be allocated on a pro rata
basis based upon net sales of each respective product by the applicable operating unit during the most recent quarter. 
  

	1.	COST OF GOODS SOLD 

“Cost of Goods Sold” means all Manufacturing Costs that are directly and reasonably attributable to manufacturing of
ZIOPHARM Product for commercial sale in the countries where such ZIOPHARM Product has been launched. 
 1.1
“Manufacturing Costs” means, with respect to ZIOPHARM Products, the FTE costs (under a reasonable accounting mechanism to be agreed upon by the Parties and out-of-pocket costs of a Party or any of its Affiliates incurred in
manufacturing such ZIOPHARM Products, including costs and expenses incurred in connection with (1) the development or validation of any manufacturing process, formulations or delivery systems, or improvements to the foregoing;
(2) manufacturing scale-up; (3) in-process testing, stability testing and release testing; (4) quality assurance/quality control development; (5) internal and Third Party costs and expenses incurred in connection with
qualification and validation of Third Party contract manufacturers, including scale up, process and equipment validation, and initial manufacturing licenses, approvals and inspections; (6) packaging development and final packaging and labeling;
(7) shipping configurations and shipping studies; and (8) overseeing the conduct of any of the foregoing. “Manufacturing Costs” shall further include: 

(a) to the extent that any such ZIOPHARM Product is Manufactured by a Third Party manufacturer, the out-of-pocket costs incurred by
such Party or any of its Affiliates to the Third Party for the manufacture and supply (including packaging and labeling) thereof, and any reasonable out-of-pocket costs and direct labor costs incurred by such Party or any of its Affiliates in
managing or overseeing the Third Party relationship determined in accordance with the books and records of such Party or its Affiliates maintained in accordance with US GAAP; and 

(b) to the extent that any such ZIOPHARM Product is manufactured by such Party or any of its Affiliates, direct material and
direct labor costs attributable to such ZIOPHARM Product, as well as reasonably allocable overhead expenses, determined in accordance with the books and records of such Party or its Affiliates maintained in accordance with US GAAP. 

 

	2.	MARKETING EXPENSES. 

 “Marketing Expenses” means the sum of Selling Expenses, Marketing
Management Expenses, Market and Consumer Research Expenses, Advertising Expenses, Trade Promotion Expenses, and Consumer Promotion Expenses, each of which is specified below, in each case to the extent directly and reasonably attributable to the
sale, promotion or marketing of the applicable ZIOPHARM Products in the countries where such ZIOPHARM Product has been launched. 
 2.1 “Selling Expenses” shall mean all reasonable costs and expenses directly associated with the efforts of field sales representatives with respect to ZIOPHARM Products in the
Territory. The costs of detailing sales calls shall be allocated based on field force time at an accounting charge rate reasonably and consistently applied within and across its operating units and which is no less favorable to the ZIOPHARM Products
than the internal charge rate used by ZIOPHARM for its own internal cost accounting purposes for products other than ZIOPHARM Products (excluding internal profit margins and markups). 

2.2 “Marketing Management Expenses” means all reasonable product management and sales promotion management
compensation (including customary bonuses and benefits but excluding stock-based compensation) and departmental expenses, including product related public relations, relationships with opinion leaders and professional societies, health care
economics studies, contract pricing and administration, market information systems, governmental affairs activities for reimbursement, formulary acceptance and other activities directly related to the ZIOPHARM Products in the Territory, management
and administration of managed care and national accounts and other activities associated with developing overall sales and marketing strategies and planning for ZIOPHARM Products in the Territory. 

2.3 “Market and Consumer Research Expenses” means all reasonable compensation (including customary bonuses and
benefits but excluding stock-based compensation) and departmental expenses for market and consumer research personnel and payments to Third Parties related to and to the extent use for conducting and monitoring professional and consumer appraisals
of existing, new or proposed ZIOPHARM Products in the Territory such as market share services (e.g., IMS data), special research testing and focus groups. 
 2.4 “Advertising Expenses” shall mean all reasonable costs reasonably incurred for the advertising and promotion of ZIOPHARM Products in the Territory. 

2.5 “Trade Promotion Expenses” means the actual and reasonable allowances given to retailers, brokers,
distributors, hospital buying groups, etc. for purchasing, promoting, and distribution of ZIOPHARM Products in the Territory. This shall include purchasing, advertising, new distribution, and display allowances as well as free goods, wholesale
allowances and reasonable field sales samples (at the out of pocket cost). 
 2.6 “Consumer Promotion
Expenses” means all reasonable expenses associated with programs to promote ZIOPHARM Products directly to the end user in the Territory. This category shall include expenses associated with promoting products directly to the professional
community such as professional samples, professional literature, promotional material costs, patient aids and detailing aids. 

	3.	DISTRIBUTION EXPENSES. 

 “Distribution Expenses” means the reasonable costs, excluding overhead, incurred by ZIOPHARM that are directly and reasonably allocable to the distribution of a ZIOPHARM
Product with respect to a particular country where such ZIOPHARM Product has been launched, excluding any costs included as a deduction in calculating Net Sales. 
  

	4.	ADDITIONAL COMMERCIALIZATION EXPENSES. 

“Additional Commercialization Expenses” means the sum of Regulatory and Related Costs, Third Party Blocking IP Costs,
Patent and Trademark Costs, Product Liability Costs, and Additional Approved Expenses, each of which is specified below, in each case to the extent directly and reasonably attributable to the commercialization of the applicable ZIOPHARM Products.

 4.1 “Regulatory and Related Costs” means all reasonable costs and expenses associated with the
preparation and filing of marketing and pricing approval applications, and the maintenance of marketing approvals, for ZIOPHARM Products, including (i) fees paid to regulatory authorities directly related to NDAs and Marketing Approvals in the
Field, (ii) costs of any regulatory interactions with respect to ZIOPHARM Products, (iii) costs incurred in securing reimbursement approvals from public and private payers, and (iv) costs to establish and maintain a global safety
database. 
 4.2 “Third Party Blocking IP Costs” means royalties, license fees or other payments, as
applicable, reasonably allocable to the development, manufacture or Commercialization of ZIOPHARM Products paid or payable to Third Parties to license Blocking Third Party IP owned or controlled by such Third Parties. 

4.3 “Patent and Trademark Costs” means all reasonable costs and expenses incurred by ZIOPHARM or its Affiliates
in connection with (i) the preparation, filing, prosecution, maintenance and enforcement of ZIOPHARM Program Patents, and (ii) establishing, maintaining and enforcing the Patents and trademarks for ZIOPHARM Products in the Territory.

 4.4 “Product Liability Costs” means the reasonable costs associated with (i) any recall in the
Territory, including the cost of any investigations or corrective actions, (ii) any Excess Product Liability Costs, and (iii) product liability insurance premiums for policies covering the development, manufacture or Commercialization of
ZIOPHARM Products (as described in Section 9.5). 
 4.5 “Additional Approved Expenses” means any
additional costs and/or expenses that are incurred in connection with the commercialization of ZIOPHARM Products and that are approved in advance, in writing, by the Intrexon representatives on the CC. 

 

	5.	POST-LAUNCH PRODUCT R&D EXPENSES. 

“Post-Launch Product R&D Expenses” means the reasonable costs, excluding administrative expenses and costs that are
included within Costs of Goods Sold, of Phase 4 

 
clinical trials and ongoing product support (including manufacturing and quality assurance technical support, and laboratory and clinical efforts directed toward the further understanding of
product safety and efficacy) and medical affairs (including regulatory support necessary for product maintenance), in each case that are (a) specifically attributable to a ZIOPHARM Product in the countries of the Territory where such ZIOPHARM
Product has been launched and (b) approved by both Parties in writing. 
 6. NO DUPLICATION. No item
of cost shall be duplicated in any of the categories comprising Allowable Expenses or in the deductions permitted under Net Sales or Sublicensing Revenue. 

 FIRST AMENDMENT TO EXCLUSIVE CHANNEL PARTNER AGREEMENT 

THIS FIRST AMENDMENT is entered into as of this 13th day of September, 2011 and serves to amend the Exclusive Channel Partner Agreement entered into by and between
Intrexon Corporation (“Intrexon”) and ZIOPHARM Oncology, Inc. (“ZIOPHARM”), on January 6, 2011 (the “Agreement”). 
 WHEREAS, both Intrexon and ZIOPHARM have a mutual interest in amending the Agreement. 
 NOW, THEREFORE, the first sentence of Section 2.3(a) of the Agreement is hereby replaced in its entirety with the following: 
 “For the JSC, each Party shall designate an equal number of representatives who are employees of such Party or an Affiliate of such Party (not to exceed four (4) for each Party) with appropriate
expertise to serve as members of the JSC. For Committees other than the JSC, each Party shall designate an equal number of representatives who are employees of such Party or an Affiliate of such Party (not to exceed three (3) for each Party)
with appropriate expertise to serve as members of such Committee; provided, however, the Parties may, from time to time, increase the total number of representatives of one or more of such Committees by one (1) additional representative per
Party (not to exceed four (4) for each Party) by agreement in writing, without further amendment of this Agreement. Third Security shall be deemed to be an Affiliate of Intrexon solely for purposes of this Section 2.3).” 

All other terms and conditions of the Agreement remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have duly executed this First Amendment to Exclusive Channel Partner Agreement by authorized
representative as of the date written above. 
 INTREXON CORPORATION 
 By: /s/ Glenn Nedwin 
 Name: Glenn Nedwin, Ph.D. 

Title: President, Human Therapeutics Division 

ZIOPHARM ONCOLOGY, INC. 
 By: /s/ Jonathan
Lewis 
 Name: Jonathan Lewis, MD, PhD 
 Title: Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]